{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:10:06Z","timestamp":1793725806874,"version":"4.6.1"},"reference-count":249,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171189"],"award-info":[{"award-number":["82171189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971020"],"award-info":[{"award-number":["81971020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41380-026-03603-6","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T06:20:56Z","timestamp":1776147656000},"page":"5114-5130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical innovations and future directions of nanoparticles in the treatment of psychiatric and neurological disorders"],"prefix":"10.1038","volume":"31","author":[{"given":"Ting-ting","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan\u2011miao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-0439","authenticated-orcid":false,"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-9627","authenticated-orcid":false,"given":"Jian-jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"3603_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204\u201322.","journal-title":"Lancet"},{"key":"3603_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"GBD 2015 Neurological Disorders Collaborator Group","year":"2017","unstructured":"GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16:877\u201397.","journal-title":"Lancet Neurol"},{"key":"3603_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/epirev\/mxh001","volume":"26","author":"C Muntaner","year":"2004","unstructured":"Muntaner C, Eaton WW, Miech R, O\u2019Campo P. Socioeconomic position and major mental disorders. Epidemiol Rev. 2004;26:53\u201362. https:\/\/doi.org\/10.1093\/epirev\/mxh001","journal-title":"Epidemiol Rev"},{"key":"3603_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S1474-4422(19)30029-8","volume":"18","author":"WM Carroll","year":"2019","unstructured":"Carroll WM. The global burden of neurological disorders. Lancet Neurol. 2019;18:418\u20139. https:\/\/doi.org\/10.1016\/S1474-4422(19)30029-8","journal-title":"Lancet Neurol"},{"key":"3603_CR5","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jama.2023.4809","volume":"329","author":"TJ Bommersbach","year":"2023","unstructured":"Bommersbach TJ, McKean AJ, Olfson M, Rhee TG. National trends in mental health-related emergency department visits among youth, 2011-20. JAMA. 2023;329:1469\u201377. https:\/\/doi.org\/10.1001\/jama.2023.4809","journal-title":"JAMA"},{"key":"3603_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.tins.2022.12.004","volume":"46","author":"H Hampel","year":"2023","unstructured":"Hampel H, Gao P, Cummings J, Toschi N, Thompson PM, Hu Y, et al. The foundation and architecture of precision medicine in neurology and psychiatry. Trends Neurosci. 2023;46:176\u201398. https:\/\/doi.org\/10.1016\/j.tins.2022.12.004","journal-title":"Trends Neurosci"},{"key":"3603_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","volume":"6","author":"H Gao","year":"2016","unstructured":"Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B. 2016;6:268\u201386. https:\/\/doi.org\/10.1016\/j.apsb.2016.05.013","journal-title":"Acta Pharm Sin B"},{"key":"3603_CR8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2174\/1389200221666200508074348","volume":"21","author":"S Raman","year":"2020","unstructured":"Raman S, Mahmood S, Hilles AR, Javed MN, Azmana M, Al-Japairai KAS. Polymeric nanoparticles for brain drug delivery - A review. Curr Drug Metab. 2020;21:649\u201360. https:\/\/doi.org\/10.2174\/1389200221666200508074348","journal-title":"Curr Drug Metab"},{"key":"3603_CR9","doi-asserted-by":"publisher","first-page":"106209","DOI":"10.1016\/j.neubiorev.2025.106209","volume":"174","author":"R Murayama","year":"2025","unstructured":"Murayama R, Cai Y, Nakamura H, Hashimoto K. Demyelination in psychiatric and neurological disorders: Mechanisms, clinical impact, and novel therapeutic strategies. Neurosci Biobehav Rev. 2025;174:106209 https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106209","journal-title":"Neurosci Biobehav Rev"},{"key":"3603_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14:388\u2013405. https:\/\/doi.org\/10.1016\/S1474-4422(15)70016-5","journal-title":"Lancet Neurol"},{"key":"3603_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14:133\u201350. https:\/\/doi.org\/10.1038\/nrneurol.2017.188","journal-title":"Nat Rev Neurol"},{"key":"3603_CR12","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","volume":"21","author":"C Soto","year":"2018","unstructured":"Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21:1332\u201340. https:\/\/doi.org\/10.1038\/s41593-018-0235-9","journal-title":"Nat Neurosci"},{"key":"3603_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101\u201324. https:\/\/doi.org\/10.1038\/s41573-020-0090-8","journal-title":"Nat Rev Drug Discov"},{"key":"3603_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8:217 https:\/\/doi.org\/10.1038\/s41392-023-01481-w","journal-title":"Signal Transduct Target Ther"},{"key":"3603_CR15","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/pharmaceutics14061283","volume":"14","author":"WM Pardridge","year":"2022","unstructured":"Pardridge WM. A historical review of brain drug delivery. Pharmaceutics. 2022;14:1283 https:\/\/doi.org\/10.3390\/pharmaceutics14061283","journal-title":"Pharmaceutics"},{"key":"3603_CR16","doi-asserted-by":"publisher","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","volume":"15","author":"R Tenchov","year":"2021","unstructured":"Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles \u2500 From liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15:16982\u20137015. https:\/\/doi.org\/10.1021\/acsnano.1c04996","journal-title":"ACS Nano"},{"key":"3603_CR17","doi-asserted-by":"publisher","first-page":"024104","DOI":"10.1088\/1748-605X\/abdc97","volume":"16","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Sun T, Jiang C. Recent advances on drug delivery nanocarriers for cerebral disorders. Biomed Mater. 2021;16:024104 https:\/\/doi.org\/10.1088\/1748-605X\/abdc97","journal-title":"Biomed Mater"},{"key":"3603_CR18","doi-asserted-by":"publisher","first-page":"21733","DOI":"10.1039\/c9nr09347h","volume":"11","author":"JA Kulkarni","year":"2019","unstructured":"Kulkarni JA, Witzigmann D, Leung J, Tam YYC, Cullis PR. On the role of helper lipids in lipid nanoparticle formulations of siRNA. Nanoscale. 2019;11:21733\u20139. https:\/\/doi.org\/10.1039\/c9nr09347h","journal-title":"Nanoscale"},{"key":"3603_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","volume":"99","author":"X Cheng","year":"2016","unstructured":"Cheng X, Lee RJ. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016;99:129\u201337. https:\/\/doi.org\/10.1016\/j.addr.2016.01.022","journal-title":"Adv Drug Deliv Rev"},{"key":"3603_CR20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted dug delivery. Front Pharmacol. 2015;6:286 https:\/\/doi.org\/10.3389\/fphar.2015.00286","journal-title":"Front Pharmacol"},{"key":"3603_CR21","doi-asserted-by":"publisher","first-page":"e10143","DOI":"10.1002\/btm2.10143","volume":"4","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019;4:e10143 https:\/\/doi.org\/10.1002\/btm2.10143","journal-title":"Bioeng Transl Med"},{"key":"3603_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ijpharm.2016.03.014","volume":"510","author":"GD Mogo\u015fanu","year":"2016","unstructured":"Mogo\u015fanu GD, Grumezescu AM, Bejenaru C, Bejenaru LE. Polymeric protective agents for nanoparticles in drug delivery and targeting. Int J Pharm. 2016;510:419\u201329. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.03.014","journal-title":"Int J Pharm"},{"key":"3603_CR23","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.3390\/molecules25163731","volume":"25","author":"A Zieli\u0144ska","year":"2020","unstructured":"Zieli\u0144ska A, Carreir\u00f3 F, Oliveira AM, Neves A, Pires B, Venkatesh DN, et al. Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology. Molecules. 2020;25:3731 https:\/\/doi.org\/10.3390\/molecules25163731","journal-title":"Molecules"},{"key":"3603_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.progpolymsci.2016.05.005","volume":"60","author":"Z Tang","year":"2016","unstructured":"Tang Z, He C, Tian H, Ding J, Hsiao BS, Chu B, et al. Polymeric nanostructured materials for biomedical applications. Prog Polymer Sci. 2016;60:86\u2013128.","journal-title":"Prog Polymer Sci"},{"key":"3603_CR25","doi-asserted-by":"publisher","first-page":"e1801362","DOI":"10.1002\/adma.201801362","volume":"30","author":"D Furtado","year":"2018","unstructured":"Furtado D, Bj\u00f6rnmalm M, Ayton S, Bush AI, Kempe K, Caruso F. Overcoming the blood-brain barrier: The role of nanomaterials in treating neurological diseases. Adv Mater. 2018;30:e1801362 https:\/\/doi.org\/10.1002\/adma.201801362","journal-title":"Adv Mater"},{"key":"3603_CR26","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.2174\/138161206779026245","volume":"12","author":"SR Croy","year":"2006","unstructured":"Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Des. 2006;12:4669\u201384. https:\/\/doi.org\/10.2174\/138161206779026245","journal-title":"Curr Pharm Des"},{"key":"3603_CR27","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.3390\/polym14214702","volume":"14","author":"K Kuperkar","year":"2022","unstructured":"Kuperkar K, Patel D, Atanase LI, Bahadur P. Amphiphilic block copolymers: their structures, and self-assembly to polymeric micelles and polymersomes as drug delivery vehicles. Polymers (Basel). 2022;14:4702 https:\/\/doi.org\/10.3390\/polym14214702","journal-title":"Polymers (Basel)"},{"key":"3603_CR28","doi-asserted-by":"publisher","first-page":"e1701276","DOI":"10.1002\/adhm.201701276","volume":"7","author":"J Leong","year":"2018","unstructured":"Leong J, Teo JY, Aakalu VK, Yang YY, Kong H. Engineering polymersomes for diagnostics and therapy. Adv Healthc Mater. 2018;7:e1701276 https:\/\/doi.org\/10.1002\/adhm.201701276","journal-title":"Adv Healthc Mater"},{"key":"3603_CR29","doi-asserted-by":"publisher","first-page":"8572","DOI":"10.1039\/c8cs00162f","volume":"47","author":"E Rideau","year":"2018","unstructured":"Rideau E, Dimova R, Schwille P, Wurm FR, Landfester K. Liposomes and polymersomes: a comparative review towards cell mimicking. Chem Soc Rev. 2018;47:8572\u2013610. https:\/\/doi.org\/10.1039\/c8cs00162f","journal-title":"Chem Soc Rev"},{"key":"3603_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/cn400182z","volume":"5","author":"L Xu","year":"2014","unstructured":"Xu L, Zhang H, Wu Y. Dendrimer advances for the central nervous system delivery of therapeutics. ACS Chem Neurosci. 2014;5:2\u201313. https:\/\/doi.org\/10.1021\/cn400182z","journal-title":"ACS Chem Neurosci"},{"key":"3603_CR31","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3390\/molecules22091401","volume":"22","author":"L Palmerston Mendes","year":"2017","unstructured":"Palmerston Mendes L, Pan J, Torchilin VP. Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules. 2017;22:1401 https:\/\/doi.org\/10.3390\/molecules22091401","journal-title":"Molecules"},{"key":"3603_CR32","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.nano.2010.04.003","volume":"6","author":"BS Sekhon","year":"2010","unstructured":"Sekhon BS, Kamboj SR. Inorganic nanomedicine-part 2. Nanomedicine. 2010;6:612\u20138.","journal-title":"Nanomedicine"},{"key":"3603_CR33","doi-asserted-by":"publisher","first-page":"e2201740","DOI":"10.1016\/j.nano.2010.04.003","volume":"9","author":"M Luo","year":"2022","unstructured":"Luo M, Lee LKC, Peng B, Choi CHJ, Tong WY, Voelcker NH. Delivering the promise of gene therapy with nanomedicines in treating central nervous system diseases. Adv Sci (Weinh). 2022;9:e2201740 https:\/\/doi.org\/10.1016\/j.nano.2010.04.003","journal-title":"Adv Sci (Weinh)"},{"key":"3603_CR34","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1021\/acsomega.9b04150","volume":"5","author":"J Wang","year":"2019","unstructured":"Wang J, Potocny AM, Rosenthal J, Day ES. Gold nanoshell-linear tetrapyrrole conjugates for near infrared-activated dual photodynamic and photothermal therapies. ACS Omega. 2019;5:926\u201340. https:\/\/doi.org\/10.1021\/acsomega.9b04150","journal-title":"ACS Omega"},{"key":"3603_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2023.103312","volume":"42","author":"MA Dheyab","year":"2023","unstructured":"Dheyab MA, Aziz AA, Khaniabadi PM, Jameel MS, Oladzadabbasabadi N, Rahman AA, et al. Gold nanoparticles-based photothermal therapy for breast cancer. Photodiagnosis Photodyn Ther. 2023;42:103312 https:\/\/doi.org\/10.1016\/j.pdpdt.2023.103312","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"3603_CR36","doi-asserted-by":"publisher","unstructured":"Croissant JG, Fatieiev Y, Almalik A, Khashab NM. Mesoporous silica and organosilica nanoparticles: physical chemistry, biosafety, delivery strategies, and biomedical applications. Adv Healthc Mater. 2018;7:1700831 https:\/\/doi.org\/10.1002\/adhm.201700831.","DOI":"10.1002\/adhm.201700831"},{"key":"3603_CR37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.biomaterials.2007.08.050","volume":"29","author":"B Chertok","year":"2008","unstructured":"Chertok B, Moffat BA, David AE, Yu F, Bergemann C, Ross BD, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008;29:487\u201396. https:\/\/doi.org\/10.1016\/j.biomaterials.2007.08.050","journal-title":"Biomaterials"},{"key":"3603_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.biomaterials.2018.05.053","volume":"197","author":"C Wang","year":"2019","unstructured":"Wang C, Lin G, Luan Y, Ding J, Li PC, Zhao Z, et al. HIF-prolyl hydroxylase 2 silencing using siRNA delivered by MRI-visible nanoparticles improves therapy efficacy of transplanted EPCs for ischemic stroke. Biomaterials. 2019;197:229\u201343. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.05.053","journal-title":"Biomaterials"},{"key":"3603_CR39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/antibiotics7020046","volume":"7","author":"LS Arias","year":"2018","unstructured":"Arias LS, Pessan JP, Vieira APM, Lima TMT, Delbem ACB, Monteiro DR. Iron oxide nanoparticles for biomedical applications: A perspective on synthesis, drugs, antimicrobial activity, and toxicity. Antibiotics (Basel). 2018;7:46 https:\/\/doi.org\/10.3390\/antibiotics7020046","journal-title":"Antibiotics (Basel)"},{"key":"3603_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.02.039","volume":"127","author":"BB Manshian","year":"2017","unstructured":"Manshian BB, Jim\u00e9nez J, Himmelreich U, Soenen SJ. Personalized medicine and follow-up of therapeutic delivery through exploitation of quantum dot toxicity. Biomaterials. 2017;127:1\u201312. https:\/\/doi.org\/10.1016\/j.biomaterials.2017.02.039","journal-title":"Biomaterials"},{"key":"3603_CR41","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.3390\/molecules25194377","volume":"25","author":"A Mohanty","year":"2020","unstructured":"Mohanty A, Uthaman S, Park IK. Utilization of polymer-lipid hybrid nanoparticles for targeted anti-cancer therapy. Molecules. 2020;25:4377 https:\/\/doi.org\/10.3390\/molecules25194377","journal-title":"Molecules"},{"key":"3603_CR42","doi-asserted-by":"publisher","first-page":"5694","DOI":"10.3390\/molecules28155694","volume":"28","author":"F Yanar","year":"2023","unstructured":"Yanar F, Carugo D, Zhang X. Hybrid nanoplatforms comprising organic nanocompartments encapsulating inorganic nanoparticles for enhanced drug delivery and bioimaging applications. Molecules. 2023;28:5694 https:\/\/doi.org\/10.3390\/molecules28155694","journal-title":"Molecules"},{"key":"3603_CR43","doi-asserted-by":"publisher","first-page":"984252","DOI":"10.3389\/fimmu.2022.984252","volume":"13","author":"MA Dobrovolskaia","year":"2022","unstructured":"Dobrovolskaia MA. Lessons learned from immunological characterization of nanomaterials at the nanotechnology characterization laboratory. Front Immunol. 2022;13:984252 https:\/\/doi.org\/10.3389\/fimmu.2022.984252","journal-title":"Front Immunol"},{"key":"3603_CR44","doi-asserted-by":"publisher","first-page":"105979","DOI":"10.1016\/j.jddst.2024.105979","volume":"99","author":"R Saker","year":"2024","unstructured":"Saker R, Regdon G, Sov\u00e1ny T. Pharmacokinetics and toxicity of inorganic nanoparticles and the physicochemical properties\/factors affecting them. J Drug Deliv Sci Technol. 2024;99:105979 https:\/\/doi.org\/10.1016\/j.jddst.2024.105979","journal-title":"J Drug Deliv Sci Technol."},{"key":"3603_CR45","doi-asserted-by":"publisher","first-page":"124163","DOI":"10.1016\/j.ijpharm.2024.124163","volume":"657","author":"C Camacho Vieira","year":"2024","unstructured":"Camacho Vieira C, Peltonen L, Karttunen AP, Ribeiro AJ. Is it advantageous to use quality by design (QbD) to develop nanoparticle-based dosage forms for parenteral drug administration? Int J Pharm. 2024;657:124163 https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124163","journal-title":"Int J Pharm"},{"key":"3603_CR46","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/nnano.2012.207","volume":"7","author":"MP Monopoli","year":"2012","unstructured":"Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012;7:779\u201386. https:\/\/doi.org\/10.1038\/nnano.2012.207","journal-title":"Nat Nanotechnol."},{"key":"3603_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2:3\u201314. https:\/\/doi.org\/10.1602\/neurorx.2.1.3","journal-title":"NeuroRx"},{"key":"3603_CR48","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.addr.2014.01.008","volume":"72","author":"M Aryal","year":"2014","unstructured":"Aryal M, Arvanitis CD, Alexander PM, McDannold N. Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv Drug Deliv Rev. 2014;72:94\u2013109. https:\/\/doi.org\/10.1016\/j.addr.2014.01.008","journal-title":"Adv Drug Deliv Rev"},{"key":"3603_CR49","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1016\/j.xphs.2020.06.008","volume":"109","author":"D Omata","year":"2020","unstructured":"Omata D, Hagiwara F, Munakata L, Shima T, Kageyama S, Suzuki Y, et al. Characterization of brain-targeted drug delivery enhanced by a combination of lipid-based microbubbles and non-focused ultrasound. J Pharm Sci. 2020;109:2827\u201335. https:\/\/doi.org\/10.1016\/j.xphs.2020.06.008","journal-title":"J Pharm Sci"},{"key":"3603_CR50","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.addr.2017.06.002","volume":"113","author":"JY Ljubimova","year":"2017","unstructured":"Ljubimova JY, Sun T, Mashouf L, Ljubimov AV, Israel LL, Ljubimov VA, et al. Covalent nano delivery systems for selective imaging and treatment of brain tumors. Adv Drug Deliv Rev. 2017;113:177\u2013200. https:\/\/doi.org\/10.1016\/j.addr.2017.06.002","journal-title":"Adv Drug Deliv Rev"},{"key":"3603_CR51","doi-asserted-by":"publisher","first-page":"119491","DOI":"10.1016\/j.biomaterials.2019.119491","volume":"224","author":"J Xie","year":"2019","unstructured":"Xie J, Shen Z, Anraku Y, Kataoka K, Chen X. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019;224:119491 https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119491","journal-title":"Biomaterials"},{"key":"3603_CR52","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jconrel.2019.11.037","volume":"317","author":"Y Luo","year":"2020","unstructured":"Luo Y, Yang H, Zhou YF, Hu B. Dual and multi-targeted nanoparticles for site-specific brain drug delivery. J Control Release. 2020;317:195\u2013215. https:\/\/doi.org\/10.1016\/j.jconrel.2019.11.037","journal-title":"J Control Release"},{"key":"3603_CR53","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/01.wco.0000186842.51129.cb","volume":"18","author":"SM Henley","year":"2005","unstructured":"Henley SM, Bates GP, Tabrizi SJ. Biomarkers for neurodegenerative diseases. Curr Opin Neurol. 2005;18:698\u2013705. https:\/\/doi.org\/10.1097\/01.wco.0000186842.51129.cb","journal-title":"Curr Opin Neurol"},{"key":"3603_CR54","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","volume":"115","author":"J Iqbal","year":"2010","unstructured":"Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115:1026\u201336. https:\/\/doi.org\/10.1182\/blood-2009-06-227579","journal-title":"Blood"},{"key":"3603_CR55","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/14737175.2020.1782746","volume":"20","author":"R Bonomo","year":"2020","unstructured":"Bonomo R, Cavaletti G, Skene DJ. Metabolomics markers in Neurology: current knowledge and future perspectives for therapeutic targeting. Expert Rev Neurother. 2020;20:725\u201338. https:\/\/doi.org\/10.1080\/14737175.2020.1782746","journal-title":"Expert Rev Neurother"},{"key":"3603_CR56","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","volume":"372","author":"FS Collins","year":"2015","unstructured":"Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793\u20135. https:\/\/doi.org\/10.1056\/NEJMp1500523","journal-title":"N Engl J Med"},{"key":"3603_CR57","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1016\/j.biomaterials.2012.03.058","volume":"33","author":"H Gao","year":"2012","unstructured":"Gao H, Qian J, Cao S, Yang Z, Pang Z, Pan S, et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials. 2012;33:5115\u201323. https:\/\/doi.org\/10.1016\/j.biomaterials.2012.03.058","journal-title":"Biomaterials"},{"key":"3603_CR58","doi-asserted-by":"publisher","first-page":"12320","DOI":"10.1002\/anie.201403036","volume":"53","author":"T Sun","year":"2014","unstructured":"Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl. 2014;53:12320\u201364. https:\/\/doi.org\/10.1002\/anie.201403036","journal-title":"Angew Chem Int Ed Engl"},{"key":"3603_CR59","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1021\/acs.chemrev.5b00346","volume":"116","author":"N Kamaly","year":"2016","unstructured":"Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116:2602\u201363. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00346","journal-title":"Chem Rev"},{"key":"3603_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1749-6632.1971.tb46890.x","volume":"179","author":"JR Gillette","year":"1971","unstructured":"Gillette JR. Factors affecting drug metabolism. Ann N Y Acad Sci. 1971;179:43\u201366. https:\/\/doi.org\/10.1111\/j.1749-6632.1971.tb46890.x","journal-title":"Ann N Y Acad Sci"},{"key":"3603_CR61","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/s1056-8719(00)00110-6","volume":"44","author":"S Ekins","year":"2000","unstructured":"Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wrighton SA. Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods. 2000;44:313\u201324. https:\/\/doi.org\/10.1016\/s1056-8719(00)00110-6","journal-title":"J Pharmacol Toxicol Methods"},{"key":"3603_CR62","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.3390\/molecules26195905","volume":"26","author":"S Adepu","year":"2021","unstructured":"Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021;26:5905 https:\/\/doi.org\/10.3390\/molecules26195905","journal-title":"Molecules"},{"key":"3603_CR63","doi-asserted-by":"publisher","first-page":"119292","DOI":"10.1016\/j.biomaterials.2019.119292","volume":"217","author":"WC Ballance","year":"2019","unstructured":"Ballance WC, Qin EC, Chung HJ, Gillette MU, Kong H. Reactive oxygen species-responsive drug delivery systems for the treatment of neurodegenerative diseases. Biomaterials. 2019;217:119292 https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119292","journal-title":"Biomaterials"},{"key":"3603_CR64","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41586-022-04875-y","volume":"607","author":"Z Diamantopoulou","year":"2022","unstructured":"Diamantopoulou Z, Castro-Giner F, Schwab FD, Foerster C, Saini M, Budinjas S, et al. The metastatic spread of breast cancer accelerates during sleep. Nature. 2022;607:156\u201362. https:\/\/doi.org\/10.1038\/s41586-022-04875-y","journal-title":"Nature"},{"key":"3603_CR65","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nmat3776","volume":"12","author":"S Mura","year":"2013","unstructured":"Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12:991\u20131003. https:\/\/doi.org\/10.1038\/nmat3776","journal-title":"Nat Mater"},{"key":"3603_CR66","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s11095-022-03246-6","volume":"39","author":"I Loryan","year":"2022","unstructured":"Loryan I, Reichel A, Feng B, Bundgaard C, Shaffer C, Kalvass C, et al. Unbound brain-to-plasma partition coefficient, Kp,uu,brain-a game changing parameter for CNS drug discovery and development. Pharm Res. 2022;39:1321\u201341. https:\/\/doi.org\/10.1007\/s11095-022-03246-6","journal-title":"Pharm Res"},{"key":"3603_CR67","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.2174\/1570159X19666210826125341","volume":"19","author":"E Aky\u00fcz","year":"2021","unstructured":"Aky\u00fcz E, K\u00f6kl\u00fc B, Ozenen C, Arulsamy A, Shaikh MF. Elucidating the potential side effects of current anti-seizure drugs for epilepsy. Curr Neuropharmacol. 2021;19:1865\u201383. https:\/\/doi.org\/10.2174\/1570159X19666210826125341","journal-title":"Curr Neuropharmacol"},{"key":"3603_CR68","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/164_2020_405","volume":"273","author":"I Loryan","year":"2022","unstructured":"Loryan I, Hammarlund-Udenaes M, Syv\u00e4nen S. Brain distribution of drugs: pharmacokinetic considerations. Handb Exp Pharmacol. 2022;273:121\u201350. https:\/\/doi.org\/10.1007\/164_2020_405","journal-title":"Handb Exp Pharmacol"},{"key":"3603_CR69","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20\u201337. https:\/\/doi.org\/10.1038\/nrc.2016.108","journal-title":"Nat Rev Cancer"},{"key":"3603_CR70","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s11845-022-03244-y","volume":"192","author":"SS Bhujbal","year":"2023","unstructured":"Bhujbal SS, Kad MM, Patole VC. Recent diagnostic techniques for the detection of Alzheimer\u2019s disease: a short review. Ir J Med Sci. 2023;192:2417\u201326. https:\/\/doi.org\/10.1007\/s11845-022-03244-y","journal-title":"Ir J Med Sci"},{"key":"3603_CR71","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41392-022-01082-z","volume":"7","author":"H Xu","year":"2022","unstructured":"Xu H, Li S, Liu YS. Nanoparticles in the diagnosis and treatment of vascular aging and related diseases. Signal Transduct Target Ther. 2022;7:231 https:\/\/doi.org\/10.1038\/s41392-022-01082-z","journal-title":"Signal Transduct Target Ther"},{"key":"3603_CR72","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.sjbs.2013.11.001","volume":"21","author":"KK Alharbi","year":"2014","unstructured":"Alharbi KK, Al-Sheikh YA. Role and implications of nanodiagnostics in the changing trends of clinical diagnosis. Saudi J Biol Sci. 2014;21:109\u201317. https:\/\/doi.org\/10.1016\/j.sjbs.2013.11.001","journal-title":"Saudi J Biol Sci"},{"key":"3603_CR73","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/B978-0-12-416020-0.00011-5","volume":"104","author":"PV Baptista","year":"2011","unstructured":"Baptista PV, Doria G, Quaresma P, Cavadas M, Neves CS, Gomes I, et al. Nanoparticles in molecular diagnostics. Prog Mol Biol Transl Sci. 2011;104:427\u201388. https:\/\/doi.org\/10.1016\/B978-0-12-416020-0.00011-5","journal-title":"Prog Mol Biol Transl Sci"},{"key":"3603_CR74","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-1-0716-3362-5_8","volume":"2699","author":"V Vedarethinam","year":"2023","unstructured":"Vedarethinam V, Jeevanandam J, Acquah C, Danquah MK. Magnetic nanoparticles for protein separation and purification. Methods Mol Biol. 2023;2699:125\u201359. https:\/\/doi.org\/10.1007\/978-1-0716-3362-5_8","journal-title":"Methods Mol Biol"},{"key":"3603_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02123-7","volume":"21","author":"TD Le","year":"2023","unstructured":"Le TD, Suttikhana I, Ashaolu TJ. State of the art on the separation and purification of proteins by magnetic nanoparticles. J Nanobiotechnology. 2023;21:363 https:\/\/doi.org\/10.1186\/s12951-023-02123-7","journal-title":"J Nanobiotechnology"},{"key":"3603_CR76","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jconrel.2020.01.009","volume":"320","author":"LL Israel","year":"2020","unstructured":"Israel LL, Galstyan A, Holler E, Ljubimova JY. Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain. J Control Release. 2020;320:45\u201362. https:\/\/doi.org\/10.1016\/j.jconrel.2020.01.009","journal-title":"J Control Release"},{"key":"3603_CR77","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.actbio.2018.05.004","volume":"74","author":"J Yao","year":"2018","unstructured":"Yao J, Li P, Li L, Yang M. Biochemistry and biomedicine of quantum dots: from biodetection to bioimaging, drug discovery, diagnostics, and therapy. Acta Biomater. 2018;74:36\u201355. https:\/\/doi.org\/10.1016\/j.actbio.2018.05.004","journal-title":"Acta Biomater"},{"key":"3603_CR78","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/bios13010029","volume":"13","author":"J Yang","year":"2022","unstructured":"Yang J, Wang X, Sun Y, Chen B, Hu F, Guo C, et al. Recent advances in colorimetric sensors based on gold nanoparticles for pathogen detection. Biosensors (Basel). 2022;13:29 https:\/\/doi.org\/10.3390\/bios13010029","journal-title":"Biosensors (Basel)"},{"key":"3603_CR79","doi-asserted-by":"publisher","first-page":"17014","DOI":"10.1038\/natrevmats.2017.14","volume":"2","author":"SM Park","year":"2017","unstructured":"Park SM, Aalipour A, Vermesh O, Yu JH, Gambhir SS. Towards clinically translatable in vivo nanodiagnostics. Nat Rev Mater. 2017;2:17014 https:\/\/doi.org\/10.1038\/natrevmats.2017.14","journal-title":"Nat Rev Mater"},{"key":"3603_CR80","doi-asserted-by":"publisher","first-page":"102697","DOI":"10.1016\/j.pdpdt.2021.102697","volume":"37","author":"J Kadkhoda","year":"2022","unstructured":"Kadkhoda J, Tarighatnia A, Barar J, Aghanejad A, Davaran S. Recent advances and trends in nanoparticles based photothermal and photodynamic therapy. Photodiagnosis Photodyn Ther. 2022;37:102697 https:\/\/doi.org\/10.1016\/j.pdpdt.2021.102697","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"3603_CR81","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1021\/acsnano.0c06415","volume":"14","author":"Y Wang","year":"2020","unstructured":"Wang Y, Luo S, Wu Y, Tang P, Liu J, Liu Z, et al. Highly penetrable and on-demand oxygen release with tumor activity composite nanosystem for photothermal\/photodynamic synergetic therapy. ACS Nano. 2020;14:17046\u201362. https:\/\/doi.org\/10.1021\/acsnano.0c06415","journal-title":"ACS Nano"},{"key":"3603_CR82","doi-asserted-by":"publisher","first-page":"920162","DOI":"10.3389\/fbioe.2022.920162","volume":"10","author":"L Chen","year":"2022","unstructured":"Chen L, Huang J, Li X, Huang M, Zeng S, Zheng J, et al. Progress of nanomaterials in photodynamic therapy against tumor. Front Bioeng Biotechnol. 2022;10:920162 https:\/\/doi.org\/10.3389\/fbioe.2022.920162","journal-title":"Front Bioeng Biotechnol"},{"key":"3603_CR83","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6:1769\u201392. https:\/\/doi.org\/10.3390\/cancers6031769","journal-title":"Cancers (Basel)"},{"key":"3603_CR84","doi-asserted-by":"publisher","first-page":"102350","DOI":"10.1016\/j.mib.2023.102350","volume":"75","author":"T Gabald\u00f3n","year":"2023","unstructured":"Gabald\u00f3n T. Nothing makes sense in drug resistance except in the light of evolution. Curr Opin Microbiol. 2023;75:102350 https:\/\/doi.org\/10.1016\/j.mib.2023.102350","journal-title":"Curr Opin Microbiol"},{"key":"3603_CR85","doi-asserted-by":"publisher","first-page":"bbab293","DOI":"10.1093\/bib\/bbab293","volume":"22","author":"B G\u00fcven\u00e7 Paltun","year":"2021","unstructured":"G\u00fcven\u00e7 Paltun B, Kaski S, Mamitsuka H. Machine learning approaches for drug combination therapies. Brief Bioinform. 2021;22:bbab293 https:\/\/doi.org\/10.1093\/bib\/bbab293","journal-title":"Brief Bioinform"},{"key":"3603_CR86","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1200\/JCO.2008.17.5844","volume":"27","author":"M Di Maio","year":"2009","unstructured":"Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:1836\u201343. https:\/\/doi.org\/10.1200\/JCO.2008.17.5844","journal-title":"J Clin Oncol"},{"key":"3603_CR87","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.bcp.2012.01.008","volume":"83","author":"CM Hu","year":"2012","unstructured":"Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol. 2012;83:1104\u201311. https:\/\/doi.org\/10.1016\/j.bcp.2012.01.008","journal-title":"Biochem Pharmacol"},{"key":"3603_CR88","doi-asserted-by":"publisher","first-page":"120347","DOI":"10.1016\/j.biomaterials.2020.120347","volume":"261","author":"MK Shim","year":"2020","unstructured":"Shim MK, Moon Y, Yang S, Kim J, Cho H, Lim S, et al. Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy. Biomaterials. 2020;261:120347 https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120347","journal-title":"Biomaterials"},{"key":"3603_CR89","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.3390\/cancers14174123","volume":"14","author":"MM Khan","year":"2022","unstructured":"Khan MM, Torchilin VP. Recent trends in nanomedicine-based strategies to overcome multidrug resistance in tumors. Cancers (Basel). 2022;14:4123 https:\/\/doi.org\/10.3390\/cancers14174123","journal-title":"Cancers (Basel)"},{"key":"3603_CR90","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.3390\/pharmaceutics14071470","volume":"14","author":"SSK Yalamarty","year":"2022","unstructured":"Yalamarty SSK, Filipczak N, Li X, Pathrikar TV, Cotter C, Torchilin VP. Co-delivery of siRNA and chemotherapeutic drug using 2C5 antibody-targeted dendrimer-based mixed micelles for multidrug resistant cancers. Pharmaceutics. 2022;14:1470 https:\/\/doi.org\/10.3390\/pharmaceutics14071470","journal-title":"Pharmaceutics"},{"key":"3603_CR91","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/ijms22010385","volume":"22","author":"W Najahi-Missaoui","year":"2020","unstructured":"Najahi-Missaoui W, Arnold RD, Cummings BS. Safe nanoparticles: are we there yet? Int J Mol Sci. 2020;22:385 https:\/\/doi.org\/10.3390\/ijms22010385","journal-title":"Int J Mol Sci"},{"key":"3603_CR92","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40035-018-0107-y","volume":"7","author":"X Du","year":"2018","unstructured":"Du X, Wang X, Geng M. Alzheimer\u2019s disease hypothesis and related therapies. Transl Neurodegener. 2018;7:2 https:\/\/doi.org\/10.1186\/s40035-018-0107-y","journal-title":"Transl Neurodegener"},{"key":"3603_CR93","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2174\/1389450120666191118123151","volume":"21","author":"G Altinoglu","year":"2020","unstructured":"Altinoglu G, Adali T. Alzheimer\u2019s disease targeted nano-based drug delivery systems. Curr Drug Targets. 2020;21:628\u201346. https:\/\/doi.org\/10.2174\/1389450120666191118123151","journal-title":"Curr Drug Targets"},{"key":"3603_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16:71 https:\/\/doi.org\/10.1186\/s12951-018-0392-8","journal-title":"J Nanobiotechnology"},{"key":"3603_CR95","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3390\/polym13091431","volume":"13","author":"FP Mutingwende","year":"2021","unstructured":"Mutingwende FP, Kondiah PPD, Ubanako P, Marimuthu T, Choonara YE. Advances in nano-enabled platforms for the treatment of depression. Polymers (Basel). 2021;13:1431 https:\/\/doi.org\/10.3390\/polym13091431","journal-title":"Polymers (Basel)"},{"key":"3603_CR96","doi-asserted-by":"publisher","first-page":"e1906050","DOI":"10.1002\/adma.201906050","volume":"32","author":"L Jin","year":"2020","unstructured":"Jin L, Hu P, Wang Y, Wu L, Qin K, Cheng H, et al. Fast-acting black-phosphorus-assisted depression therapy with low toxicity. Adv Mater. 2020;32:e1906050 https:\/\/doi.org\/10.1002\/adma.201906050","journal-title":"Adv Mater"},{"key":"3603_CR97","doi-asserted-by":"publisher","first-page":"112533","DOI":"10.1016\/j.exger.2024.112533","volume":"195","author":"M Dadkhah","year":"2024","unstructured":"Dadkhah M, Afshari S, Samizadegan T, Shirmard LR, Barin S. Pegylated chitosan nanoparticles of fluoxetine enhance cognitive performance and hippocampal brain derived neurotrophic factor levels in a rat model of local demyelination. Exp Gerontol. 2024;195:112533 https:\/\/doi.org\/10.1016\/j.exger.2024.112533","journal-title":"Exp Gerontol"},{"key":"3603_CR98","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.3390\/ijms22041640","volume":"22","author":"K Suneson","year":"2021","unstructured":"Suneson K, Lindahl J, Chamli H\u00e5rsmar S, S\u00f6derberg G, Lindqvist D. Inflammatory depression-mechanisms and non-pharmacological interventions. Int J Mol Sci. 2021;22:1640 https:\/\/doi.org\/10.3390\/ijms22041640","journal-title":"Int J Mol Sci"},{"key":"3603_CR99","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.drudis.2020.05.001","volume":"25","author":"S Bhatt","year":"2020","unstructured":"Bhatt S, Nagappa AN, Patil CR. Role of oxidative stress in depression. Drug Discov Today. 2020;25:1270\u20136. https:\/\/doi.org\/10.1016\/j.drudis.2020.05.001","journal-title":"Drug Discov Today"},{"key":"3603_CR100","doi-asserted-by":"publisher","first-page":"e12598","DOI":"10.1111\/jpi.12598","volume":"67","author":"G Mannino","year":"2019","unstructured":"Mannino G, Caradonna F, Cruciata I, Lauria A, Perrone A, Gentile C. Melatonin reduces inflammatory response in human intestinal epithelial cells stimulated by interleukin-1\u03b2. J Pineal Res. 2019;67:e12598 https:\/\/doi.org\/10.1111\/jpi.12598","journal-title":"J Pineal Res"},{"key":"3603_CR101","doi-asserted-by":"publisher","first-page":"e2108525","DOI":"10.1002\/adma.202108525","volume":"34","author":"Y Liu","year":"2022","unstructured":"Liu Y, Hu P, Zheng Z, Zhong D, Xie W, Tang Z, et al. Photoresponsive vaccine-like CAR-M system with high-efficiency central immune regulation for inflammation-related depression. Adv Mater. 2022;34:e2108525 https:\/\/doi.org\/10.1002\/adma.202108525","journal-title":"Adv Mater"},{"key":"3603_CR102","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1021\/acs.nanolett.2c01334","volume":"22","author":"S Fu","year":"2022","unstructured":"Fu S, Chen H, Yang W, Xia X, Zhao S, Xu X, et al. ROS-targeted depression therapy via BSA-incubated ceria nanoclusters. Nano Lett. 2022;22:4519\u201327.","journal-title":"Nano Lett"},{"key":"3603_CR103","doi-asserted-by":"publisher","first-page":"6731","DOI":"10.1039\/c5tb01159k","volume":"3","author":"F Liu","year":"2015","unstructured":"Liu F, He X, Zhang J, Chen H, Zhang H, Wang Z. Controllable synthesis of polydopamine nanoparticles in microemulsions with pH-activatable properties for cancer detection and treatment. J Mater Chem B. 2015;3:6731\u20139. https:\/\/doi.org\/10.1039\/c5tb01159k","journal-title":"J Mater Chem B."},{"key":"3603_CR104","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fbioe.2018.00109","volume":"6","author":"V Ball","year":"2018","unstructured":"Ball V. Polydopamine nanomaterials: Recent advances in synthesis methods and applications. Front Bioeng Biotechnol. 2018;6:109 https:\/\/doi.org\/10.3389\/fbioe.2018.00109","journal-title":"Front Bioeng Biotechnol"},{"key":"3603_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01807-4","volume":"21","author":"TT Zhu","year":"2023","unstructured":"Zhu TT, Wang H, Gu HW, Ju LS, Wu XM, Pan WT, et al. Melanin-like polydopamine nanoparticles mediating anti-inflammatory and rescuing synaptic loss for inflammatory depression therapy. J Nanobiotechnology. 2023;21:52 https:\/\/doi.org\/10.1186\/s12951-023-01807-4","journal-title":"J Nanobiotechnology"},{"key":"3603_CR106","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.7150\/thno.121735","volume":"16","author":"PM Liu","year":"2026","unstructured":"Liu PM, Wang YG, Zhu TT, Zhang JC, Gu HW, Li HJ, et al. Polydopamine nanoparticles restore cognition via targeted dopamine delivery and septo-hippocampal cholinergic activation. Theranostics. 2026;16:3616\u201333. https:\/\/doi.org\/10.7150\/thno.121735","journal-title":"Theranostics"},{"key":"3603_CR107","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","volume":"27","author":"Y Wei","year":"2022","unstructured":"Wei Y, Chang L, Hashimoto K. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Mol Psychiatry. 2022;27:559\u201373. https:\/\/doi.org\/10.1038\/s41380-021-01121-1","journal-title":"Mol Psychiatry"},{"key":"3603_CR108","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1038\/s41380-022-01587-7","volume":"27","author":"K Hashimoto","year":"2022","unstructured":"Hashimoto K. Ketamine: anesthetic, psychotomimetic, antidepressant, or anthelmintic? Mol Psychiatry. 2022;27:3116\u20138. https:\/\/doi.org\/10.1038\/s41380-022-01587-7","journal-title":"Mol Psychiatry"},{"key":"3603_CR109","doi-asserted-by":"publisher","first-page":"104762","DOI":"10.1016\/j.neubiorev.2022.104762","volume":"139","author":"X Wang","year":"2022","unstructured":"Wang X, Yang J, Hashimoto K. R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression. Neurosci Biobehav Rev. 2022;139:104762 https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104762","journal-title":"Neurosci Biobehav Rev"},{"key":"3603_CR110","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jatmed.2024.07.001","volume":"3","author":"K Hashimoto","year":"2024","unstructured":"Hashimoto K, Zhao M, Zhu T, Wang X, Yang J. Ketamine and its two enantiomers in anesthesiology and psychiatry: A historical review and future directions. J Anes Transl Med. 2024;3:65\u201375. https:\/\/doi.org\/10.1016\/j.jatmed.2024.07.001","journal-title":"J Anes Transl Med"},{"key":"3603_CR111","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1126\/science.adx4559","volume":"388","author":"K Hashimoto","year":"2025","unstructured":"Hashimoto K. Extending ketamine\u2019s antidepressant effects. Science. 2025;388:589\u201390. https:\/\/doi.org\/10.1126\/science.adx4559","journal-title":"Science"},{"key":"3603_CR112","doi-asserted-by":"publisher","first-page":"eadv5986","DOI":"10.1126\/sciadv.adv5986","volume":"11","author":"L He","year":"2025","unstructured":"He L, Wang X, Luo S, Jiang N, Yan Y, Xie M, et al. Microglial BDNF modulates arketamine\u2019s antidepressant-like effects through cortico-accumbal pathways. Sci Adv. 2025;11:eadv5986 https:\/\/doi.org\/10.1126\/sciadv.adv5986","journal-title":"Sci Adv"},{"key":"3603_CR113","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00406-025-02066-0","volume":"275","author":"MM Zhao","year":"2025","unstructured":"Zhao MM, Yang JJ, Hashimoto K. Ketamine and its enantiomers in treatment-resistant depression: promise, pitfalls, and personalized psychiatry. Eur Arch Psychiatry Clin Neurosci. 2025;275:1267\u20139. https:\/\/doi.org\/10.1007\/s00406-025-02066-0","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3603_CR114","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2147\/IJN.S400798","volume":"18","author":"H Zhang","year":"2023","unstructured":"Zhang H, Zhou P, Jiang Y, Li L, Ju F, Cheng Q, et al. Sustained-release esketamine based nanoparticle-hydrogel delivery system for neuropathic pain management. Int J Nanomedicine. 2023;18:1131\u201343. https:\/\/doi.org\/10.2147\/IJN.S400798","journal-title":"Int J Nanomedicine"},{"key":"3603_CR115","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/bmb\/ldv017","volume":"114","author":"J Lally","year":"2015","unstructured":"Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114:169\u201379. https:\/\/doi.org\/10.1093\/bmb\/ldv017","journal-title":"Br Med Bull"},{"key":"3603_CR116","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(19)31135-3","journal-title":"Lancet"},{"key":"3603_CR117","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ddr.21331","volume":"77","author":"Y Sun","year":"2016","unstructured":"Sun Y, Kang C, Liu F, Song L. Delivery of antipsychotics with nanoparticles. Drug Dev Res. 2016;77:393\u20139. https:\/\/doi.org\/10.1002\/ddr.21331","journal-title":"Drug Dev Res"},{"key":"3603_CR118","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1016\/j.xphs.2019.08.027","volume":"108","author":"RS Annu","year":"2019","unstructured":"Annu RS, Md S, Baboota S, Ali J. Analyzing nanotheraputics-based approaches for the management of psychotic disorders. J Pharm Sci. 2019;108:3757\u201368. https:\/\/doi.org\/10.1016\/j.xphs.2019.08.027","journal-title":"J Pharm Sci"},{"key":"3603_CR119","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.2217\/nnm.14.164","volume":"9","author":"MS Muthu","year":"2014","unstructured":"Muthu MS, Agrawal P, Singh RP. Antipsychotic nanomedicine: a successful platform for clinical use. Nanomedicine (Lond). 2014;9:2071\u20134. https:\/\/doi.org\/10.2217\/nnm.14.164","journal-title":"Nanomedicine (Lond)"},{"key":"3603_CR120","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1021\/acs.molpharmaceut.5b00402","volume":"12","author":"YK Katare","year":"2015","unstructured":"Katare YK, Daya RP, Sookram Gray C, Luckham RE, Bhandari J, Chauhan AS, et al. Brain targeting of a water insoluble antipsychotic drug haloperidol via the intranasal route using PAMAM dendrimer. Mol Pharm. 2015;12:3380\u20138. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00402","journal-title":"Mol Pharm"},{"key":"3603_CR121","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.msec.2016.04.089","volume":"66","author":"K Sawant","year":"2016","unstructured":"Sawant K, Pandey A, Patel S. Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics. Mater Sci Eng C Mater Biol Appl. 2016;66:230\u201343. https:\/\/doi.org\/10.1016\/j.msec.2016.04.089","journal-title":"Mater Sci Eng C Mater Biol Appl."},{"key":"3603_CR122","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","volume":"209","author":"D Siskind","year":"2016","unstructured":"Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209:385\u201392. https:\/\/doi.org\/10.1192\/bjp.bp.115.177261","journal-title":"Br J Psychiatry"},{"key":"3603_CR123","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1192\/bjp.2024.255","volume":"227","author":"K Hashimoto","year":"2025","unstructured":"Hashimoto K. Host microbiota in clozapine-induced ileus and pneumonia among people with schizophrenia. Br J Psychiatry. 2025;227:574\u20135. https:\/\/doi.org\/10.1192\/bjp.2024.255","journal-title":"Br J Psychiatry"},{"key":"3603_CR124","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jconrel.2004.01.005","volume":"95","author":"V Venkateswarlu","year":"2004","unstructured":"Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004;95:627\u201338. https:\/\/doi.org\/10.1016\/j.jconrel.2004.01.005","journal-title":"J Control Release"},{"key":"3603_CR125","doi-asserted-by":"publisher","first-page":"102533","DOI":"10.1016\/j.jddst.2021.102533","volume":"64","author":"HP Patel","year":"2021","unstructured":"Patel HP, Gandhi P, Chaudhari PS, Desai BV, Desai DT, Dedhiya PP, et al. Clozapine loaded nanostructured lipid carriers engineered for brain targeting via nose-to-brain delivery: Optimization and in vivo pharmacokinetic studies. J Drug Deliv Sci Technol. 2021;64:102533 https:\/\/doi.org\/10.1016\/j.jddst.2021.102533","journal-title":"J Drug Deliv Sci Technol."},{"key":"3603_CR126","doi-asserted-by":"publisher","first-page":"113862","DOI":"10.1016\/j.colsurfb.2024.113862","volume":"237","author":"HP Patel","year":"2024","unstructured":"Patel HP, Desai PH, Patel RV, Lodha SN, Gore AH, Patil PO, et al. Clozapine-laden carbon dots delivered to the brain via an intranasal pathway: Synthesis, characterization, ex vivo, and in vivo studies. Colloids Surf B Biointerfaces. 2024;237:113862 https:\/\/doi.org\/10.1016\/j.colsurfb.2024.113862","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3603_CR127","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s11095-023-03551-8","volume":"40","author":"AC Funguetto-Ribeiro","year":"2023","unstructured":"Funguetto-Ribeiro AC, Maciel TR, Lunardi AG, Gomes DB, Ibarra M, Haas SE. Clozapine-loaded nanocapsules improve antipsychotic activity in rats: building a sequential PopPK\/PD model to discriminate nanocarriers in the preformulation step. Pharm Res. 2023;40:1751\u201363. https:\/\/doi.org\/10.1007\/s11095-023-03551-8","journal-title":"Pharm Res"},{"key":"3603_CR128","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/2045125314540297","volume":"4","author":"S Brissos","year":"2014","unstructured":"Brissos S, Veguilla MR, Taylor D, Balanz\u00e1-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4:198\u2013219. https:\/\/doi.org\/10.1177\/2045125314540297","journal-title":"Ther Adv Psychopharmacol"},{"key":"3603_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"CU Correll","year":"2016","unstructured":"Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77:1\u201324. https:\/\/doi.org\/10.4088\/JCP.15032su1","journal-title":"J Clin Psychiatry"},{"key":"3603_CR130","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/pharmaceutics15020678","volume":"15","author":"MD Ferreira","year":"2023","unstructured":"Ferreira MD, Duarte J, Veiga F, Paiva-Santos AC, Pires PC. Nanosystems for brain targeting of antipsychotic drugs: An update on the most promising nanocarriers for increased bioavailability and therapeutic efficacy. Pharmaceutics. 2023;15:678 https:\/\/doi.org\/10.3390\/pharmaceutics15020678","journal-title":"Pharmaceutics"},{"key":"3603_CR131","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","volume":"9","author":"NR Mirza","year":"2003","unstructured":"Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 2003;9:159\u201386. https:\/\/doi.org\/10.1111\/j.1527-3458.2003.tb00247.x","journal-title":"CNS Drug Rev"},{"key":"3603_CR132","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.biopsych.2024.03.014","volume":"96","author":"SM Paul","year":"2024","unstructured":"Paul SM, Yohn SE, Brannan SK, Neugebauer NM, Breier A. Muscarinic receptor activators as novel treatments for schizophrenia. Biol Psychiatry. 2024;96:627\u201337. https:\/\/doi.org\/10.1016\/j.biopsych.2024.03.014","journal-title":"Biol Psychiatry"},{"key":"3603_CR133","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2017015","journal-title":"N Engl J Med"},{"key":"3603_CR134","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403:160\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(23)02190-6","journal-title":"Lancet"},{"key":"3603_CR135","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","volume":"81","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A randomized clinical trial. JAMA Psychiatry. 2024;81:749\u201356. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0785","journal-title":"JAMA Psychiatry"},{"key":"3603_CR136","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Amieva H, Petersen RC, Ch\u00e9telat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7:33 https:\/\/doi.org\/10.1038\/s41572-021-00269-y","journal-title":"Nat Rev Dis Primers"},{"key":"3603_CR137","doi-asserted-by":"publisher","first-page":"113320","DOI":"10.1016\/j.ejmech.2021.113320","volume":"216","author":"S Srivastava","year":"2021","unstructured":"Srivastava S, Ahmad R, Khare SK. Alzheimer\u2019s disease and its treatment by different approaches: A review. Eur J Med Chem. 2021;216:113320 https:\/\/doi.org\/10.1016\/j.ejmech.2021.113320","journal-title":"Eur J Med Chem"},{"key":"3603_CR138","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jconrel.2010.11.033","volume":"152","author":"JK Sahni","year":"2011","unstructured":"Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C. Neurotherapeutic applications of nanoparticles in Alzheimer\u2019s disease. J Control Release. 2011;152:208\u201331. https:\/\/doi.org\/10.1016\/j.jconrel.2010.11.033","journal-title":"J Control Release"},{"key":"3603_CR139","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ijbiomac.2019.02.156","volume":"130","author":"J Gupta","year":"2019","unstructured":"Gupta J, Fatima MT, Islam Z, Khan RH, Uversky VN, Salahuddin P. Nanoparticle formulations in the diagnosis and therapy of Alzheimer\u2019s disease. Int J Biol Macromol. 2019;130:515\u201326. https:\/\/doi.org\/10.1016\/j.ijbiomac.2019.02.156","journal-title":"Int J Biol Macromol"},{"key":"3603_CR140","doi-asserted-by":"publisher","first-page":"114139","DOI":"10.1016\/j.colsurfb.2024.114139","volume":"244","author":"X Bi","year":"2024","unstructured":"Bi X, Cao N, He J. Recent advances in nanoenzymes for Alzheimer\u2019s disease treatment. Colloids Surf B Biointerfaces. 2024;244:114139 https:\/\/doi.org\/10.1016\/j.colsurfb.2024.114139","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3603_CR141","doi-asserted-by":"publisher","first-page":"10632","DOI":"10.3390\/ijms251910632","volume":"25","author":"M Menendez-Gonzalez","year":"2024","unstructured":"Menendez-Gonzalez M. Intrathecal immunoselective nanopheresis for Alzheimer\u2019s disease: what and how? why and when? Int J Mol Sci. 2024;25:10632 https:\/\/doi.org\/10.3390\/ijms251910632","journal-title":"Int J Mol Sci"},{"key":"3603_CR142","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fnmol.2020.00137","volume":"13","author":"J Zhao","year":"2020","unstructured":"Zhao J, Liu X, Xia W, Zhang Y, Wang C. Targeting amyloidogenic processing of APP in Alzheimer\u2019s disease. Front Mol Neurosci. 2020;13:137 https:\/\/doi.org\/10.3389\/fnmol.2020.00137","journal-title":"Front Mol Neurosci"},{"key":"3603_CR143","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nn1531","volume":"8","author":"O Singer","year":"2005","unstructured":"Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci. 2005;8:1343\u20139. https:\/\/doi.org\/10.1038\/nn1531","journal-title":"Nat Neurosci"},{"key":"3603_CR144","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jconrel.2018.04.034","volume":"279","author":"P Wang","year":"2018","unstructured":"Wang P, Zheng X, Guo Q, Yang P, Pang X, Qian K, et al. Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer\u2019s disease. J Control Release. 2018;279:220\u201333. https:\/\/doi.org\/10.1016\/j.jconrel.2018.04.034","journal-title":"J Control Release"},{"key":"3603_CR145","doi-asserted-by":"publisher","first-page":"119752","DOI":"10.1016\/j.biomaterials.2019.119752","volume":"232","author":"C Ren","year":"2020","unstructured":"Ren C, Li D, Zhou Q, Hu X. Mitochondria-targeted TPP-MoS2 with dual enzyme activity provides efficient neuroprotection through M1\/M2 microglial polarization in an Alzheimer\u2019s disease model. Biomaterials. 2020;232:119752 https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119752","journal-title":"Biomaterials"},{"key":"3603_CR146","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.jcis.2023.07.132","volume":"650","author":"P Ye","year":"2023","unstructured":"Ye P, Li L, Qi X, Chi M, Liu J, Xie M. Macrophage membrane-encapsulated nitrogen-doped carbon quantum dot nanosystem for targeted treatment of Alzheimer\u2019s disease: Regulating metal ion homeostasis and photothermal removal of \u03b2-amyloid. J Colloid Interface Sci. 2023;650:1749\u201361. https:\/\/doi.org\/10.1016\/j.jcis.2023.07.132","journal-title":"J Colloid Interface Sci"},{"key":"3603_CR147","doi-asserted-by":"publisher","first-page":"e2303211","DOI":"10.1002\/adhm.202303211","volume":"13","author":"X Qi","year":"2023","unstructured":"Qi X, Li L, Ye P, Xie M. Macrophage membrane-modified MoS2 quantum dots as a nanodrug for combined multi-targeting of Alzheimer\u2019s disease. Adv Healthc Mater. 2023;13:e2303211 https:\/\/doi.org\/10.1002\/adhm.202303211","journal-title":"Adv Healthc Mater."},{"key":"3603_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18525-2","volume":"11","author":"K Hou","year":"2020","unstructured":"Hou K, Zhao J, Wang H, Li B, Li K, Shi X, et al. Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer\u2019s disease. Nat Commun. 2020;11:4790 https:\/\/doi.org\/10.1038\/s41467-020-18525-2","journal-title":"Nat Commun"},{"key":"3603_CR149","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.18.613794","author":"P Bhuiyan","year":"2024","unstructured":"Bhuiyan P, Zhang W, Liang G, Jiang B, Vera R, Chae R, et al. Intranasal lithium chloride nanoparticles inhibit inflammatory pyroptosis in brains and ameliorate memory loss and depression behavior in 5xFAD mice. bioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.09.18.613794. [Preprint]2024.09.18.613794","journal-title":"bioRxiv"},{"key":"3603_CR150","doi-asserted-by":"publisher","first-page":"29779","DOI":"10.1021\/acsnano.4c09449","volume":"18","author":"W Yang","year":"2024","unstructured":"Yang W, Shi Y, Zhang Y, Yang Y, Du Y, Yang Z, et al. Intranasal carrier-free nanomodulator addresses both symptomatology and etiology of Alzheimer\u2019s disease by restoring neuron plasticity and reprogramming lesion microenvironment. ACS Nano. 2024;18:29779\u201393. https:\/\/doi.org\/10.1021\/acsnano.4c09449","journal-title":"ACS Nano"},{"key":"3603_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02912-8","volume":"22","author":"Y Hu","year":"2024","unstructured":"Hu Y, Cui J, Sun J, Liu X, Gao S, Mei X, et al. A novel biomimetic nanovesicle containing caffeic acid-coupled carbon quantum dots for the the treatment of Alzheimer\u2019s disease via nasal administration. J Nanobiotechnology. 2024;22:642 https:\/\/doi.org\/10.1186\/s12951-024-02912-8","journal-title":"J Nanobiotechnology"},{"key":"3603_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","volume":"36","author":"DK Simon","year":"2020","unstructured":"Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med. 2020;36:1\u201312. https:\/\/doi.org\/10.1016\/j.cger.2019.08.002","journal-title":"Clin Geriatr Med"},{"key":"3603_CR153","doi-asserted-by":"publisher","unstructured":"Lees AJ. The on-off phenomenon. J Neurol Neurosurg Psychiatry. 1989;52:29\u201337. https:\/\/doi.org\/10.1136\/jnnp.52.suppl.29","DOI":"10.1136\/jnnp.52.suppl.29"},{"key":"3603_CR154","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.02.001","volume":"51","author":"KL Chou","year":"2018","unstructured":"Chou KL, Stacy M, Simuni T, Miyasaki J, Oertel WH, Sethi K, et al. The spectrum of \u201coff\u201d in Parkinson\u2019s disease: what have we learned over 40 years? Parkinsonism Relat Disord. 2018;51:9\u201316. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.02.001","journal-title":"Parkinsonism Relat Disord"},{"key":"3603_CR155","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00415-020-10291-x","volume":"268","author":"J Baskin","year":"2021","unstructured":"Baskin J, Jeon JE, Lewis SJG. Nanoparticles for drug delivery in Parkinson\u2019s disease. J Neurol. 2021;268:1981\u201394. https:\/\/doi.org\/10.1007\/s00415-020-10291-x","journal-title":"J Neurol"},{"key":"3603_CR156","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jconrel.2023.06.026","volume":"360","author":"EF van Vliet","year":"2023","unstructured":"van Vliet EF, Knol MJ, Schiffelers RM, Caiazzo M, Fens MHAM. Levodopa-loaded nanoparticles for the treatment of Parkinson\u2019s disease. J Control Release. 2023;360:212\u201324. https:\/\/doi.org\/10.1016\/j.jconrel.2023.06.026","journal-title":"J Control Release"},{"key":"3603_CR157","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/jnc.14713","volume":"150","author":"NN Vaikath","year":"2019","unstructured":"Vaikath NN, Hmila I, Gupta V, Erskine D, Ingelsson M, El-Agnaf OMA. Antibodies against alpha-synuclein: tools and therapies. J Neurochem. 2019;150:612\u201325. https:\/\/doi.org\/10.1111\/jnc.14713","journal-title":"J Neurochem"},{"key":"3603_CR158","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","volume":"32","author":"EJ Bae","year":"2012","unstructured":"Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, et al. Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission. J Neurosci. 2012;32:13454\u201369. https:\/\/doi.org\/10.1523\/JNEUROSCI.1292-12.2012","journal-title":"J Neurosci"},{"key":"3603_CR159","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3389\/fphar.2018.01208","volume":"9","author":"TA Slastnikova","year":"2018","unstructured":"Slastnikova TA, Ulasov AV, Rosenkranz AA, Sobolev AS. Targeted intracellular delivery of antibodies: The state of the art. Front Pharmacol. 2018;9:1208 https:\/\/doi.org\/10.3389\/fphar.2018.01208","journal-title":"Front Pharmacol"},{"key":"3603_CR160","doi-asserted-by":"publisher","first-page":"e48750","DOI":"10.7554\/eLife.48750","volume":"8","author":"JX Dong","year":"2019","unstructured":"Dong JX, Lee Y, Kirmiz M, Palacio S, Dumitras C, Moreno CM, et al. A toolbox of nanobodies developed and validated for use as intrabodies and nanoscale immunolabels in mammalian brain neurons. eLife. 2019;8:e48750 https:\/\/doi.org\/10.7554\/eLife.48750","journal-title":"eLife"},{"key":"3603_CR161","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3390\/microorganisms9091956","volume":"9","author":"N Silva-Pilipich","year":"2021","unstructured":"Silva-Pilipich N, Smerdou C, Vanrell L. A small virus to deliver small antibodies: new targeted therapies based on AAV delivery of nanobodies. Microorganisms. 2021;9:1956 https:\/\/doi.org\/10.3390\/microorganisms9091956","journal-title":"Microorganisms"},{"key":"3603_CR162","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41531-018-0062-4","volume":"4","author":"D Chatterjee","year":"2018","unstructured":"Chatterjee D, Bhatt M, Butler D, De Genst E, Dobson CM, Messer A, et al. Proteasome-targeted nanobodies alleviate pathology and functional decline in an \u03b1-synuclein-based Parkinson\u2019s disease model. NPJ Parkinsons Dis. 2018;4:25 https:\/\/doi.org\/10.1038\/s41531-018-0062-4","journal-title":"NPJ Parkinsons Dis"},{"key":"3603_CR163","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31787-2","volume":"13","author":"YR Butler","year":"2022","unstructured":"Butler YR, Liu Y, Kumbhar R, Zhao P, Gadhave K, Wang N, et al. \u03b1-Synuclein fibril-specific nanobody reduces prion-like \u03b1-synuclein spreading in mice. Nat Commun. 2022;13:4060 https:\/\/doi.org\/10.1038\/s41467-022-31787-2","journal-title":"Nat Commun"},{"key":"3603_CR164","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.brainresrev.2004.02.003","volume":"45","author":"K Hashimoto","year":"2004","unstructured":"Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev. 2004;45:104\u201314. https:\/\/doi.org\/10.1016\/j.brainresrev.2004.02.003","journal-title":"Brain Res Brain Res Rev"},{"key":"3603_CR165","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1440-1819.2010.02113.x","volume":"64","author":"K Hashimoto","year":"2010","unstructured":"Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci. 2010;64:341\u201357. https:\/\/doi.org\/10.1111\/j.1440-1819.2010.02113.x","journal-title":"Psychiatry Clin Neurosci"},{"key":"3603_CR166","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/dneu.20758","volume":"70","author":"E Castr\u00e9n","year":"2010","unstructured":"Castr\u00e9n E, Rantam\u00e4ki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol. 2010;70:289\u201397. https:\/\/doi.org\/10.1002\/dneu.20758","journal-title":"Dev Neurobiol"},{"key":"3603_CR167","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cell.2021.12.003","volume":"185","author":"CS Wang","year":"2022","unstructured":"Wang CS, Kavalali ET, Monteggia LM. BDNF signaling in context: From synaptic regulation to psychiatric disorders. Cell. 2022;185:62\u201376. https:\/\/doi.org\/10.1016\/j.cell.2021.12.003","journal-title":"Cell."},{"key":"3603_CR168","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.euroneuro.2021.04.010","volume":"50","author":"Y Wei","year":"2021","unstructured":"Wei Y, Chang L, Hashimoto K. Intranasal administration of transforming growth factor-\u03b21 elicits rapid-acting antidepressant-like effects in a chronic social defeat stress model: A role of TrkB signaling. Eur Neuropsychopharmacol. 2021;50:55\u201363. https:\/\/doi.org\/10.1016\/j.euroneuro.2021.04.010","journal-title":"Eur Neuropsychopharmacol"},{"key":"3603_CR169","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jad.2024.08.222","volume":"367","author":"D Xu","year":"2024","unstructured":"Xu D, Liu G, Zhao M, Wan X, Qu Y, Murayama R, et al. Effects of arketamine on depression-like behaviors and demyelination in mice exposed to chronic restrain stress: A role of transforming growth factor-\u03b21. J Affect Disord. 2024;367:745\u201355. https:\/\/doi.org\/10.1016\/j.jad.2024.08.222","journal-title":"J Affect Disord"},{"key":"3603_CR170","doi-asserted-by":"publisher","first-page":"177096","DOI":"10.1016\/j.ejphar.2024.177096","volume":"985","author":"MM Zhao","year":"2024","unstructured":"Zhao MM, Zhu TT, Xu D, Wan X, Liu G, Murayama R, et al. Transforming growth factor-\u03b21 mediates the beneficial effects of arketamine on demyelination and remyelination in the brains of cuprizone-treated mice. Eur J Pharmacol. 2024;985:177096 https:\/\/doi.org\/10.1016\/j.ejphar.2024.177096","journal-title":"Eur J Pharmacol"},{"key":"3603_CR171","doi-asserted-by":"publisher","first-page":"111228","DOI":"10.1016\/j.pnpbp.2024.111228","volume":"136","author":"TT Zhu","year":"2025","unstructured":"Zhu TT, Zhao MM, Xu D, Cai Y, Liu G, Murayama R, et al. Arketamine alleviates cognitive impairments and demyelination in mice with postoperative cognitive dysfunction via TGF-\u03b21 activation. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111228 https:\/\/doi.org\/10.1016\/j.pnpbp.2024.111228","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3603_CR172","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/s0006-3223(03)00181-1","volume":"54","author":"E Shimizu","year":"2003","unstructured":"Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54:70\u20135. https:\/\/doi.org\/10.1016\/s0006-3223(03)00181-1","journal-title":"Biol Psychiatry"},{"key":"3603_CR173","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.intimp.2006.03.015","volume":"6","author":"KM Lee","year":"2006","unstructured":"Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol. 2006;6:1298\u2013304. https:\/\/doi.org\/10.1016\/j.intimp.2006.03.015","journal-title":"Int Immunopharmacol"},{"key":"3603_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.95","volume":"7","author":"B Yang","year":"2017","unstructured":"Yang B, Ren Q, Zhang JC, Chen QX, Hashimoto K. Altered expression of BDNF, BDNF pro-peptide and their precursor proBDNF in brain and liver tissues from psychiatric disorders: rethinking the brain-liver axis. Transl Psychiatry. 2017;7:e1128 https:\/\/doi.org\/10.1038\/tp.2017.95","journal-title":"Transl Psychiatry"},{"key":"3603_CR175","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.psychres.2013.12.009","volume":"215","author":"T Niitsu","year":"2014","unstructured":"Niitsu T, Ishima T, Yoshida T, Hashimoto T, Matsuzawa D, Shirayama Y, et al. A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Res. 2014;215:268\u201373. https:\/\/doi.org\/10.1016\/j.psychres.2013.12.009","journal-title":"Psychiatry Res"},{"key":"3603_CR176","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neulet.2014.05.034","volume":"575","author":"T Niitsu","year":"2014","unstructured":"Niitsu T, Shirayama Y, Matsuzawa D, Shimizu E, Hashimoto K, Iyo M. Association between serum levels of glial cell-line derived neurotrophic factor and attention deficits in schizophrenia. Neurosci Lett. 2014;575:37\u201341. https:\/\/doi.org\/10.1016\/j.neulet.2014.05.034","journal-title":"Neurosci Lett"},{"key":"3603_CR177","doi-asserted-by":"publisher","first-page":"113967","DOI":"10.1016\/j.psychres.2021.113967","volume":"301","author":"K Idemoto","year":"2021","unstructured":"Idemoto K, Niitsu T, Hata T, Ishima T, Yoshida S, Hattori K, et al. Serum levels of glial cell line-derived neurotrophic factor as a biomarker for mood disorders and lithium response. Psychiatry Res. 2021;301:113967 https:\/\/doi.org\/10.1016\/j.psychres.2021.113967","journal-title":"Psychiatry Res"},{"key":"3603_CR178","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/archneur.57.6.846","volume":"57","author":"C Hock","year":"2000","unstructured":"Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol. 2000;57:846\u201351. https:\/\/doi.org\/10.1001\/archneur.57.6.846","journal-title":"Arch Neurol"},{"key":"3603_CR179","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1021\/acschemneuro.4c00392","volume":"15","author":"AK Mahanta","year":"2024","unstructured":"Mahanta AK, Chaulagain B, Trivedi R, Singh J. Mannose-functionalized chitosan-coated PLGA nanoparticles for brain-targeted codelivery of CBD and BDNF for the treatment of Alzheimer\u2019s disease. ACS Chem Neurosci. 2024;15:4021\u201332. https:\/\/doi.org\/10.1021\/acschemneuro.4c00392","journal-title":"ACS Chem Neurosci"},{"key":"3603_CR180","doi-asserted-by":"publisher","first-page":"130726","DOI":"10.1016\/j.ijbiomac.2024.130726","volume":"265","author":"M D\u0105bkowska","year":"2024","unstructured":"D\u0105bkowska M, Stukan I, Kosiorowska A, Szatanik A, \u0141uczkowska K, Machali\u0144ska A, et al. In vitro and in vivo characterization of human serum albumin-based PEGylated nanoparticles for BDNF and NT3 codelivery. Int J Biol Macromol. 2024;265:130726 https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.130726","journal-title":"Int J Biol Macromol"},{"key":"3603_CR181","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.gastha.2023.08.012","volume":"3","author":"C Yang","year":"2024","unstructured":"Yang C, Mwangi SM, Balasubramaniam A, Li G, Merlin-Zhang O, Liu Y, et al. Treatment of obesity through glial cell-derived neurotrophic factor lipid nanoparticle delivery in mice. Gastro Hep Adv. 2024;3:38\u201347. https:\/\/doi.org\/10.1016\/j.gastha.2023.08.012","journal-title":"Gastro Hep Adv"},{"key":"3603_CR182","doi-asserted-by":"publisher","first-page":"970925","DOI":"10.3389\/fnins.2022.970925","volume":"16","author":"N Reich","year":"2022","unstructured":"Reich N, H\u00f6lscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: An in-depth review. Front Neurosci. 2022;16:970925 https:\/\/doi.org\/10.3389\/fnins.2022.970925","journal-title":"Front Neurosci"},{"key":"3603_CR183","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1039\/d4md00729h","volume":"16","author":"N Sehra","year":"2025","unstructured":"Sehra N, Parmar R, Jain R. Peptide-based amyloid-beta aggregation inhibitors. RSC Med Chem. 2025;16:1083\u2013104. https:\/\/doi.org\/10.1039\/d4md00729h","journal-title":"RSC Med Chem"},{"key":"3603_CR184","doi-asserted-by":"publisher","first-page":"137","DOI":"10.22037\/ijpr.2021.115705.15484","volume":"20","author":"M Xia","year":"2021","unstructured":"Xia M, Zhao T, Wang X, Li Y, Li Y, Zheng T, et al. Brain-derived neurotrophic factor and its applications through nanosystem delivery. Iran J Pharm Res. 2021;20:137\u201351. https:\/\/doi.org\/10.22037\/ijpr.2021.115705.15484","journal-title":"Iran J Pharm Res"},{"key":"3603_CR185","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.3390\/ijms23084153","volume":"23","author":"AM Hersh","year":"2022","unstructured":"Hersh AM, Alomari S, Tyler BM. Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology. Int J Mol Sci. 2022;23:4153 https:\/\/doi.org\/10.3390\/ijms23084153","journal-title":"Int J Mol Sci"},{"key":"3603_CR186","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41551-018-0314-y","volume":"2","author":"JPA Ioannidis","year":"2018","unstructured":"Ioannidis JPA, Kim BYS, Trounson A. How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. Nat Biomed Eng. 2018;2:797\u2013809. https:\/\/doi.org\/10.1038\/s41551-018-0314-y","journal-title":"Nat Biomed Eng"},{"key":"3603_CR187","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41565-024-01754-7","volume":"19","author":"P Joyce","year":"2024","unstructured":"Joyce P, Allen CJ, Alonso MJ, Ashford M, Bradbury MS, Germain M, et al. A translational framework to DELIVER nanomedicines to the clinic. Nat Nanotechnol. 2024;19:1597\u2013611. https:\/\/doi.org\/10.1038\/s41565-024-01754-7","journal-title":"Nat Nanotechnol"},{"key":"3603_CR188","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil\u00ae-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020","journal-title":"J Control Release"},{"key":"3603_CR189","doi-asserted-by":"publisher","first-page":"7768","DOI":"10.1200\/JCO.2005.08.002","volume":"23","author":"M Harries","year":"2005","unstructured":"Harries M, Ellis P, Harper P. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J Clin Oncol. 2005;23:7768\u201371. https:\/\/doi.org\/10.1200\/JCO.2005.08.002","journal-title":"J Clin Oncol"},{"key":"3603_CR190","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.ajps.2018.08.003","volume":"14","author":"W Yang","year":"2019","unstructured":"Yang W, Yang Z, Liu J, Liu D, Wang Y. Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation. Asian J Pharm Sci. 2019;14:687\u201397. https:\/\/doi.org\/10.1016\/j.ajps.2018.08.003","journal-title":"Asian J Pharm Sci"},{"key":"3603_CR191","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/ptr.6571","volume":"34","author":"S Asadi","year":"2020","unstructured":"Asadi S, Gholami MS, Siassi F, Qorbani M, Sotoudeh G. Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial. Phytother Res. 2020;34:896\u2013903. https:\/\/doi.org\/10.1002\/ptr.6571","journal-title":"Phytother Res"},{"key":"3603_CR192","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-08354-9","volume":"25","author":"M Soltani","year":"2024","unstructured":"Soltani M, Hosseinzadeh-Attar MJ, Rezaei M, Alipoor E, Vasheghani-Farahani A, Yaseri M, et al. Effect of nano-curcumin supplementation on cardiometabolic risk factors, physical and psychological quality of life, and depression in patients with coronary slow flow phenomenon: a randomized double-blind clinical trial. Trials. 2024;25:515 https:\/\/doi.org\/10.1186\/s13063-024-08354-9","journal-title":"Trials"},{"key":"3603_CR193","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/JCP.0000000000001324","volume":"41","author":"M Hosseininasab","year":"2021","unstructured":"Hosseininasab M, Zarghami M, Mazhari S, Salehifar E, Moosazadeh M, Fariborzifar A, et al. Nanocurcumin as an add-on to antipsychotic drugs for treatment of negative symptoms in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2021;41:25\u201330. https:\/\/doi.org\/10.1097\/JCP.0000000000001324","journal-title":"J Clin Psychopharmacol"},{"key":"3603_CR194","doi-asserted-by":"publisher","first-page":"428","DOI":"10.14283\/jpad.2024.26","volume":"11","author":"S Guilliot","year":"2024","unstructured":"Guilliot S, Wilson EN, Touchon J, Soto ME. Nanolithium, a new treatment approach to Alzheimer\u2019s disease: A review of existing evidence and clinical perspectives. J Prev Alzheimers Dis. 2024;11:428\u201334. https:\/\/doi.org\/10.14283\/jpad.2024.26","journal-title":"J Prev Alzheimers Dis"},{"key":"3603_CR195","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3390\/pharmaceutics15051399","volume":"15","author":"R Tal\u00e9ns-Visconti","year":"2023","unstructured":"Tal\u00e9ns-Visconti R, de Juli\u00e1n-Ortiz JV, Vila-Bus\u00f3 O, Diez-Sales O, N\u00e1cher A. Intranasal drug administration in Alzheimer-type dementia: towards clinical applications. Pharmaceutics. 2023;15:1399 https:\/\/doi.org\/10.3390\/pharmaceutics15051399","journal-title":"Pharmaceutics"},{"key":"3603_CR196","unstructured":"Aphios. Safety, tolerability and efficacy assessment of intranasal nanoparticles of APH-1105, a novel alpha secretase modulator for mild to moderate cognitive impairment due to Alzheimer\u2019s disease (AD). clinicaltrials.gov; Report No.: NCT03806478. 2021"},{"key":"3603_CR197","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02236-z","volume":"21","author":"J Ren","year":"2023","unstructured":"Ren J, Dewey RB III, Rynders A, Evan J, Evan J, Ligozio S, et al. Evidence of brain target engagement in Parkinson\u2019s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials. J Nanobiotechnology. 2023;21:478 https:\/\/doi.org\/10.1186\/s12951-023-02236-z","journal-title":"J Nanobiotechnology"},{"key":"3603_CR198","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/13543784.2023.2263368","volume":"32","author":"S Vucic","year":"2023","unstructured":"Vucic S, Kiernan MC. Nanocrystalline gold (CNM-Au8): a novel bioenergetic treatment for ALS. Expert Opin Investig Drugs. 2023;32:783\u20135. https:\/\/doi.org\/10.1080\/13543784.2023.2263368","journal-title":"Expert Opin Investig Drugs"},{"key":"3603_CR199","doi-asserted-by":"publisher","first-page":"102036","DOI":"10.1016\/j.eclinm.2023.102036","volume":"60","author":"S Vucic","year":"2023","unstructured":"Vucic S, Menon P, Huynh W, Mahoney C, Ho KS, Hartford A, et al. Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension. EClinicalMedicine. 2023;60:102036 https:\/\/doi.org\/10.1016\/j.eclinm.2023.102036","journal-title":"EClinicalMedicine"},{"key":"3603_CR200","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/13543784.2023.2252738","volume":"32","author":"JD Bireley","year":"2023","unstructured":"Bireley JD, Morren JA. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS). Expert Opin Investig Drugs. 2023;32:677\u201383. https:\/\/doi.org\/10.1080\/13543784.2023.2252738","journal-title":"Expert Opin Investig Drugs"},{"key":"3603_CR201","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.3390\/molecules27092725","volume":"27","author":"D Qubty","year":"2022","unstructured":"Qubty D, Frid K, Har-Even M, Rubovitch V, Gabizon R, Pick CG. Nano-PSO administration attenuates cognitive and neuronal deficits resulting from traumatic brain injury. Molecules. 2022;27:2725 https:\/\/doi.org\/10.3390\/molecules27092725","journal-title":"Molecules"},{"key":"3603_CR202","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2217\/nnm.12.105","volume":"8","author":"U Tisch","year":"2013","unstructured":"Tisch U, Schlesinger I, Ionescu R, Nassar M, Axelrod N, Robertman D, et al. Detection of Alzheimer\u2019s and Parkinson\u2019s disease from exhaled breath using nanomaterial-based sensors. Nanomedicine (Lond). 2013;8:43\u201356. https:\/\/doi.org\/10.2217\/nnm.12.105","journal-title":"Nanomedicine (Lond)"},{"key":"3603_CR203","doi-asserted-by":"publisher","first-page":"135967","DOI":"10.1016\/j.ijbiomac.2024.135967","volume":"280","author":"K Ganguly","year":"2024","unstructured":"Ganguly K, Adhikary K, Acharjee A, Acharjee P, Trigun SK, Mutlaq AS, et al. Biological significance and pathophysiological role of matrix metalloproteinases in the central nervous system. Int J Biol Macromol. 2024;280:135967 https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.135967","journal-title":"Int J Biol Macromol"},{"key":"3603_CR204","doi-asserted-by":"publisher","first-page":"122614","DOI":"10.1016\/j.ijpharm.2023.122614","volume":"633","author":"S Ashique","year":"2023","unstructured":"Ashique S, Afzal O, Yasmin S, Hussain A, Altamimi MA, Webster TJ, et al. Strategic nanocarriers to control neurodegenerative disorders: concept, challenges, and future perspective. Int J Pharm. 2023;633:122614 https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122614","journal-title":"Int J Pharm"},{"key":"3603_CR205","doi-asserted-by":"publisher","first-page":"155451","DOI":"10.1016\/j.prp.2024.155451","volume":"260","author":"S Ashique","year":"2024","unstructured":"Ashique S, Kumar N, Mishra N, Muthu S, Rajendran RL, Chandrasekaran B, et al. Unveiling the role of exosomes as cellular messengers in neurodegenerative diseases and their potential therapeutic implications. Pathol Res Pract. 2024;260:155451 https:\/\/doi.org\/10.1016\/j.prp.2024.155451","journal-title":"Pathol Res Pract"},{"key":"3603_CR206","doi-asserted-by":"publisher","first-page":"116376","DOI":"10.1016\/j.biopha.2024.116376","volume":"174","author":"HM Albadrani","year":"2024","unstructured":"Albadrani HM, Chauhan P, Ashique S, Babu MA, Iqbal D, Almutary AG, et al. Mechanistic insights into the potential role of dietary polyphenols and their nanoformulation in the management of Alzheimer\u2019s disease. Biomed Pharmacother. 2024;174:116376 https:\/\/doi.org\/10.1016\/j.biopha.2024.116376","journal-title":"Biomed Pharmacother"},{"key":"3603_CR207","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1017\/cts.2023.537","volume":"7","author":"AM Kaizer","year":"2023","unstructured":"Kaizer AM, Belli HM, Ma Z, Nicklawsky AG, Roberts SC, Wild J, et al. Recent innovations in adaptive trial designs: A review of design opportunities in translational research. J Clin Transl Sci. 2023;7:e125 https:\/\/doi.org\/10.1017\/cts.2023.537","journal-title":"J Clin Transl Sci"},{"key":"3603_CR208","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10928-023-09850-2","volume":"50","author":"A Ruiz-Garcia","year":"2023","unstructured":"Ruiz-Garcia A, Baverel P, Bottino D, Dolton M, Feng Y, Gonz\u00e1lez-Garc\u00eda I, et al. A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. J Pharmacokinet Pharmacodyn. 2023;50:147\u201372. https:\/\/doi.org\/10.1007\/s10928-023-09850-2","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"3603_CR209","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1016\/j.xphs.2024.09.005","volume":"113","author":"JD Clogston","year":"2024","unstructured":"Clogston JD, Foss W, Harris D, Oberoi H, Pan J, Pu E, et al. Current state of nanomedicine drug products: an industry perspective. J Pharm Sci. 2024;113:3395\u2013405. https:\/\/doi.org\/10.1016\/j.xphs.2024.09.005","journal-title":"J Pharm Sci"},{"key":"3603_CR210","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1038\/s41380-022-01511-z","volume":"27","author":"EG Knox","year":"2022","unstructured":"Knox EG, Aburto MR, Clarke G, Cryan JF, O\u2019Driscoll CM. The blood-brain barrier in aging and neurodegeneration. Mol Psychiatry. 2022;27:2659\u201373. https:\/\/doi.org\/10.1038\/s41380-022-01511-z","journal-title":"Mol Psychiatry"},{"key":"3603_CR211","doi-asserted-by":"publisher","first-page":"603039","DOI":"10.3389\/fimmu.2020.603039","volume":"11","author":"NM La-Beck","year":"2021","unstructured":"La-Beck NM, Islam MR, Markiewski MM. Nanoparticle-induced complement activation: implications for cancer nanomedicine. Front Immunol. 2021;11:603039 https:\/\/doi.org\/10.3389\/fimmu.2020.603039","journal-title":"Front Immunol"},{"key":"3603_CR212","doi-asserted-by":"publisher","first-page":"7732","DOI":"10.1039\/d1cs01070k","volume":"51","author":"T Fan","year":"2022","unstructured":"Fan T, Yan L, He S, Hong Q, Ai F, He S, et al. Biodistribution, degradability and clearance of 2D materials for their biomedical applications. Chem Soc Rev. 2022;51:7732\u201351. https:\/\/doi.org\/10.1039\/d1cs01070k","journal-title":"Chem Soc Rev"},{"key":"3603_CR213","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pnpbp.2014.08.018","volume":"56","author":"K Nemani","year":"2015","unstructured":"Nemani K, Hosseini Ghomi R, McCormick B, Fan X. Schizophrenia and the gut-brain axis. Prog Neuropsychopharmacol Biol Psychiatry. 2015;56:155\u201360. https:\/\/doi.org\/10.1016\/j.pnpbp.2014.08.018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3603_CR214","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/mp.2016.44","volume":"21","author":"P Zheng","year":"2016","unstructured":"Zheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host\u2019s metabolism. Mol Psychiatry. 2016;21:786\u201396. https:\/\/doi.org\/10.1038\/mp.2016.44","journal-title":"Mol Psychiatry"},{"key":"3603_CR215","doi-asserted-by":"publisher","first-page":"eaba8555","DOI":"10.1126\/sciadv.aba8555","volume":"6","author":"J Yang","year":"2020","unstructured":"Yang J, Zheng P, Li Y, Wu J, Tan X, Zhou J, et al. Landscapes of bacterial and metabolic signatures and their interaction in major depressive disorders. Sci Adv. 2020;6:eaba8555 https:\/\/doi.org\/10.1126\/sciadv.aba8555","journal-title":"Sci Adv"},{"key":"3603_CR216","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1038\/s41380-019-0475-4","volume":"25","author":"F Zhu","year":"2020","unstructured":"Zhu F, Guo R, Wang W, Ju Y, Wang Q, Ma Q, et al. Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice. Mol Psychiatry. 2020;25:2905\u201318. https:\/\/doi.org\/10.1038\/s41380-019-0475-4","journal-title":"Mol Psychiatry"},{"key":"3603_CR217","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.brainresbull.2022.02.004","volume":"182","author":"L Chang","year":"2022","unstructured":"Chang L, Wei Y, Hashimoto K. Brain-gut-microbiota axis in depression: A historical overview and future directions. Brain Res Bull. 2022;182:44\u201356. https:\/\/doi.org\/10.1016\/j.brainresbull.2022.02.004","journal-title":"Brain Res Bull"},{"key":"3603_CR218","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.brainresbull.2022.02.008","volume":"182","author":"Y Wei","year":"2022","unstructured":"Wei Y, Wang T, Liao L, Fan X, Chang L, Hashimoto K. Brain-spleen axis in health and diseases: A review and future perspective. Brain Res Bull. 2022;182:130\u201340. https:\/\/doi.org\/10.1016\/j.brainresbull.2022.02.008","journal-title":"Brain Res Bull"},{"key":"3603_CR219","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/s41380-022-01456-3","volume":"27","author":"AJ McGuinness","year":"2022","unstructured":"McGuinness AJ, Davis JA, Dawson SL, Loughman A, Collier F, O\u2019Hely M, et al. A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. Mol Psychiatry. 2022;27:1920\u201335. https:\/\/doi.org\/10.1038\/s41380-022-01456-3","journal-title":"Mol Psychiatry"},{"key":"3603_CR220","doi-asserted-by":"publisher","first-page":"104527","DOI":"10.1016\/j.ebiom.2023.104527","volume":"90","author":"L Liu","year":"2023","unstructured":"Liu L, Wang H, Chen X, Zhang Y, Zhang H, Xie P. Gut microbiota and its metabolites in depression: from pathogenesis to treatment. EBioMedicine. 2023;90:104527 https:\/\/doi.org\/10.1016\/j.ebiom.2023.104527","journal-title":"EBioMedicine"},{"key":"3603_CR221","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1038\/s41380-023-02287-6","volume":"28","author":"K Hashimoto","year":"2023","unstructured":"Hashimoto K. Emerging role of the host microbiome in neuropsychiatric disorders: overview and future directions. Mol Psychiatry. 2023;28:3625\u201337. https:\/\/doi.org\/10.1038\/s41380-023-02287-6","journal-title":"Mol Psychiatry"},{"key":"3603_CR222","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1038\/s41380-023-02161-5","volume":"28","author":"K Hashimoto","year":"2023","unstructured":"Hashimoto K. Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein-Barr virus and the gut-brain axis. Mol Psychiatry. 2023;28:4968\u201376. https:\/\/doi.org\/10.1038\/s41380-023-02161-5","journal-title":"Mol Psychiatry"},{"key":"3603_CR223","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5056\/jnm18087","volume":"25","author":"K Kowalski","year":"2019","unstructured":"Kowalski K, Mulak A. Brain-gut-microbiota axis in Alzheimer\u2019s disease. J Neurogastroenterol Motil. 2019;25:48\u201360. https:\/\/doi.org\/10.5056\/jnm18087","journal-title":"J Neurogastroenterol Motil"},{"key":"3603_CR224","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41582-022-00681-2","volume":"18","author":"AH Tan","year":"2022","unstructured":"Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Nat Rev Neurol. 2022;18:476\u201395. https:\/\/doi.org\/10.1038\/s41582-022-00681-2","journal-title":"Nat Rev Neurol"},{"key":"3603_CR225","doi-asserted-by":"publisher","first-page":"110231","DOI":"10.1016\/j.cbi.2022.110231","volume":"368","author":"S Ashique","year":"2022","unstructured":"Ashique S, De Rubis G, Sirohi E, Mishra N, Rihan M, Garg A, et al. Short chain fatty acids: fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases. Chem Biol Interact. 2022;368:110231 https:\/\/doi.org\/10.1016\/j.cbi.2022.110231","journal-title":"Chem Biol Interact"},{"key":"3603_CR226","doi-asserted-by":"publisher","first-page":"e34092","DOI":"10.1016\/j.heliyon.2024.e34092","volume":"10","author":"S Ashique","year":"2024","unstructured":"Ashique S, Mohanto S, Ahmed MG, Mishra N, Garg A, Chellappan DK, et al. Gut-brain axis: A cutting-edge approach to target neurological disorders and potential synbiotic application. Heliyon. 2024;10:e34092 https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34092","journal-title":"Heliyon"},{"key":"3603_CR227","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1038\/s41380-025-03000-5","volume":"30","author":"D Wang","year":"2025","unstructured":"Wang D, Gui S, Pu J, Zhong X, Yan L, Li Z, et al. PsycGM: a comprehensive database for associations between gut microbiota and psychiatric disorders. Mol Psychiatry. 2025;30:4222\u201333. https:\/\/doi.org\/10.1038\/s41380-025-03000-5","journal-title":"Mol Psychiatry"},{"key":"3603_CR228","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1038\/s41380-025-03085-y","volume":"30","author":"X Feng","year":"2025","unstructured":"Feng X, Jia M, Cai M, Zhu T, Hashimoto K, Yang JJ. Central-peripheral neuroimmune dynamics in psychological stress and depression: insights from current research. Mol Psychiatry. 2025;30:4881\u201398. https:\/\/doi.org\/10.1038\/s41380-025-03085-y","journal-title":"Mol Psychiatry"},{"key":"3603_CR229","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1038\/s41380-025-03191-x","volume":"30","author":"L Liu","year":"2025","unstructured":"Liu L, Wang H, Guo S, Liu S, Du Y, Wang L, et al. The emerging role of the gut microbiome in depression: implications for precision medicine. Mol Psychiatry. 2025;30:5901\u201313. https:\/\/doi.org\/10.1038\/s41380-025-03191-x","journal-title":"Mol Psychiatry"},{"key":"3603_CR230","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbi.2024.11.023","volume":"124","author":"L Ma","year":"2025","unstructured":"Ma L, Wang HB, Hashimoto K. The vagus nerve: an old but new player in brain-body communication. Brain Behav Immun. 2025;124:28\u201339. https:\/\/doi.org\/10.1016\/j.bbi.2024.11.023","journal-title":"Brain Behav Immun"},{"key":"3603_CR231","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-024-01743-1","volume":"9","author":"JS Loh","year":"2024","unstructured":"Loh JS, Mak WQ, Tan LKS, Ng CX, Chan HH, Yeow SH, et al. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct Target Ther. 2024;9:37 https:\/\/doi.org\/10.1038\/s41392-024-01743-1","journal-title":"Signal Transduct Target Ther"},{"key":"3603_CR232","doi-asserted-by":"publisher","first-page":"13044","DOI":"10.1021\/acsnano.3c02403","volume":"17","author":"SA Ejazi","year":"2023","unstructured":"Ejazi SA, Louisthelmy R, Maisel K. Mechanisms of nanoparticle transport across intestinal tissue: An oral delivery perspective. ACS Nano. 2023;17:13044\u201361. https:\/\/doi.org\/10.1021\/acsnano.3c02403","journal-title":"ACS Nano"},{"key":"3603_CR233","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50972-x","volume":"14","author":"RP Pandey","year":"2024","unstructured":"Pandey RP, Gunjan, Himanshu, Mukherjee R, Chang CM. Nanocarrier-mediated probiotic delivery: a systematic meta-analysis assessing the biological effects. Sci Rep. 2024;14:631 https:\/\/doi.org\/10.1038\/s41598-023-50972-x","journal-title":"Sci Rep"},{"key":"3603_CR234","doi-asserted-by":"publisher","first-page":"eadf3887","DOI":"10.1126\/sciadv.adf3887","volume":"9","author":"H He","year":"2023","unstructured":"He H, Qin Q, Xu F, Chen Y, Rao S, Wang C, et al. Oral polyphenol-armored nanomedicine for targeted modulation of gut microbiota-brain interactions in colitis. Sci Adv. 2023;9:eadf3887 https:\/\/doi.org\/10.1126\/sciadv.adf3887","journal-title":"Sci Adv"},{"key":"3603_CR235","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.1021\/acs.molpharmaceut.4c00499","volume":"21","author":"H Wu","year":"2024","unstructured":"Wu H, Shi C, Li Q, Wang L, Wang R, Chen F, et al. Oral administration of bioactive nanoparticulates for inflammatory bowel disease therapy by mitigating oxidative stress and restoring intestinal microbiota homeostasis. Mol Pharm. 2024;21:6193\u2013205. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00499","journal-title":"Mol Pharm"},{"key":"3603_CR236","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41551-022-00903-4","volume":"6","author":"G Zhang","year":"2022","unstructured":"Zhang G, Wang Q, Tao W, Jiang W, Elinav E, Wang Y, et al. Glucosylated nanoparticles for the oral delivery of antibiotics to the proximal small intestine protect mice from gut dysbiosis. Nat Biomed Eng. 2022;6:867\u201381. https:\/\/doi.org\/10.1038\/s41551-022-00903-4","journal-title":"Nat Biomed Eng"},{"key":"3603_CR237","doi-asserted-by":"publisher","first-page":"eadf8782","DOI":"10.1126\/sciadv.adf8782","volume":"9","author":"B Xu","year":"2023","unstructured":"Xu B, Shaoyong W, Wang L, Yang C, Chen T, Jiang X, et al. Gut-targeted nanoparticles deliver specifically targeted antimicrobial peptides against Clostridium perfringens infections. Sci Adv. 2023;9:eadf8782 https:\/\/doi.org\/10.1126\/sciadv.adf8782","journal-title":"Sci Adv"},{"key":"3603_CR238","doi-asserted-by":"publisher","first-page":"eadg2252","DOI":"10.1126\/sciadv.adg2252","volume":"9","author":"X Wang","year":"2023","unstructured":"Wang X, Cui X, Wu J, Bao L, Tan Z, Chen C. Peripheral nerves directly mediate the transneuronal translocation of silver nanomaterials from the gut to central nervous system. Sci Adv. 2023;9:eadg2252 https:\/\/doi.org\/10.1126\/sciadv.adg2252","journal-title":"Sci Adv"},{"key":"3603_CR239","doi-asserted-by":"publisher","first-page":"19739","DOI":"10.1021\/acs.langmuir.4c02481","volume":"40","author":"H Jia","year":"2024","unstructured":"Jia H, Gong J, Hu Z, Wen T, Li C, Chen Y, et al. Antioxidant carbon dots nanozymes alleviate stress-induced depression by modulating gut microbiota. Langmuir. 2024;40:19739\u201350. https:\/\/doi.org\/10.1021\/acs.langmuir.4c02481","journal-title":"Langmuir"},{"key":"3603_CR240","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s43587-023-00516-9","volume":"3","author":"X Guo","year":"2023","unstructured":"Guo X, Li C, Zhang J, Sun M, Xu J, Xu C, et al. Chiral nanoparticle-remodeled gut microbiota alleviates neurodegeneration via the gut-brain axis. Nat Aging. 2023;3:1415\u201329. https:\/\/doi.org\/10.1038\/s43587-023-00516-9","journal-title":"Nat Aging"},{"key":"3603_CR241","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16790-8","volume":"8","author":"QJ Yu","year":"2018","unstructured":"Yu QJ, Yu SY, Zuo LJ, Lian TH, Hu Y, Wang RD, et al. Parkinson disease with constipation: clinical features and relevant factors. Sci Rep. 2018;8:567 https:\/\/doi.org\/10.1038\/s41598-017-16790-8","journal-title":"Sci Rep"},{"key":"3603_CR242","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1016\/S2589-7500(21)00275-2","volume":"4","author":"T Nedelec","year":"2022","unstructured":"Nedelec T, Couvy-Duchesne B, Monnet F, Daly T, Ansart M, Gantzer L, et al. Identifying health conditions associated with Alzheimer\u2019s disease up to 15 years before diagnosis: an agnostic study of French and British health records. Lancet Digit Health. 2022;4:e169\u2013e178. https:\/\/doi.org\/10.1016\/S2589-7500(21)00275-2","journal-title":"Lancet Digit Health."},{"key":"3603_CR243","doi-asserted-by":"publisher","first-page":"1438778","DOI":"10.3389\/fmicb.2024.1438778","volume":"15","author":"C Feng","year":"2024","unstructured":"Feng C, Gao G, Wu K, Weng X. Causal relationship between gut microbiota and constipation: a bidirectional Mendelian randomization study. Front Microbiol. 2024;15:1438778 https:\/\/doi.org\/10.3389\/fmicb.2024.1438778","journal-title":"Front Microbiol"},{"key":"3603_CR244","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1038\/s41564-024-01856-x","volume":"9","author":"N Proch\u00e1zkov\u00e1","year":"2024","unstructured":"Proch\u00e1zkov\u00e1 N, Laursen MF, La Barbera G, Tsekitsidi E, J\u00f8rgensen MS, Rasmussen MA, et al. Gut physiology and environment explain variations in human gut microbiome composition and metabolism. Nat Microbiol. 2024;9:3210\u201325. https:\/\/doi.org\/10.1038\/s41564-024-01856-x","journal-title":"Nat Microbiol"},{"key":"3603_CR245","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15508-1","volume":"11","author":"MR Charbonneau","year":"2020","unstructured":"Charbonneau MR, Isabella VM, Li N, Kurtz CB. Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat Commun. 2020;11:1738 https:\/\/doi.org\/10.1038\/s41467-020-15508-1","journal-title":"Nat Commun"},{"key":"3603_CR246","doi-asserted-by":"publisher","first-page":"S487","DOI":"10.1093\/cid\/ciad642","volume":"77","author":"AJ Gonzales-Luna","year":"2023","unstructured":"Gonzales-Luna AJ, Carlson TJ, Garey KW. Review Article: Safety of live biotherapeutic products used for the prevention of Clostridioides difficile infection recurrence. Clin Infect Dis. 2023;77:S487\u2013S496. https:\/\/doi.org\/10.1093\/cid\/ciad642","journal-title":"Clin Infect Dis"},{"key":"3603_CR247","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-022-05620-1","volume":"614","author":"M Valles-Colomer","year":"2023","unstructured":"Valles-Colomer M, Blanco-M\u00edguez A, Manghi P, Asnicar F, Dubois L, Golzato D, et al. The person-to-person transmission landscape of the gut and oral microbiomes. Nature. 2023;614:125\u201335. https:\/\/doi.org\/10.1038\/s41586-022-05620-1","journal-title":"Nature"},{"key":"3603_CR248","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41565-022-01260-8","volume":"18","author":"G Peng","year":"2023","unstructured":"Peng G, Sinkko HM, Alenius H, Lozano N, Kostarelos K, Br\u00e4utigam L, et al. Graphene oxide elicits microbiome-dependent type 2 immune responses via the aryl hydrocarbon receptor. Nat Nanotechnol. 2023;18:42\u201348. https:\/\/doi.org\/10.1038\/s41565-022-01260-8","journal-title":"Nat Nanotechnol"},{"key":"3603_CR249","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-025-00683-0","volume":"11","author":"J Rodriguez","year":"2025","unstructured":"Rodriguez J, Cordaillat-Simmons M, Pot B, Druart C. The regulatory framework for microbiome-based therapies: insights into European regulatory developments. NPJ Biofilms Microbiomes. 2025;11:53 https:\/\/doi.org\/10.1038\/s41522-025-00683-0","journal-title":"NPJ Biofilms Microbiomes"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03603-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03603-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03603-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T02:02:53Z","timestamp":1785981773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03603-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":249,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3603"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03603-6","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Hashimoto is one of the editorial board members of this journal. Dr. Hashimoto is the inventor of filed patent applications on \u201cThe use of\n                      R\n                      -Ketamine in the treatment of psychiatric diseases\u201d, \u201c(\n                      S\n                      )-norketamine and salt thereof as pharmaceutical\u201d, \u201c\n                      R\n                      -Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder\u201d, \u201cPreventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases\u201d, and \u201c\n                      R\n                      -Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder\u201d by the Chiba University. Dr. Hashimoto has also received research support from Otsuka. The other authors have no conflict of interest.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Ethics"}}]}}